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Triple-negative breast cancer (TNBC) is considered to be the most aggressive and has 
worse prognosis compared to other breast cancers and accounts for roughly 18% of all epithelial 
cancers of the breast, or carcinomas. TNBC exhibits complex molecular heterogeneity both inter- 
and intratumorally and likely consists of several distinct molecular subgroups that are currently 
unknown. Metaplastic breast carcinoma (MBC) is even more aggressive than triple-negative breast 
cancer (TNBC) but also typically presents as triple-negative histologically, and is defined by the 
admixture of both invasive glandular and non-glandular “metaplastic” heterologous elements of 
spindle, squamous or sarcomatoid subtypes.  
The protein profiles underpinning the phenotypic diversity and metastatic behavior of 
MBC are unknown. We present a quantitative multi-subtype proteomic landscape of MBC, non-
metaplastic TNBC, and normal breast from small yet well-annotated cohort of 27 patients, and 
also present the somatic mutational landscape on the same cohort. We used multiplex isobaric 
tandem mass tag (TMT) labeling for proteomics and quantified 5,798 proteins, and from whole-
exome sequencing for genomics analysis we found 980 total somatic mutational variants. MBCs 
displayed increased epithelial-to-mesenchymal transition (EMT) and extracellular matrix (ECM) 
signaling, and reduced metabolic pathways compared to TNBC.  
We discovered subtype-specific profiles among MBCs including distinct upregulated 
profiles; translation and ribosomal events in spindle, inflammation and apical junctions in 
squamous, and extracellular matrix in sarcomatoid. Comparison of the proteomes of spindle MBC 
with MMTV-cre;Ccn6fl/fl spindle MBC mouse tumors revealed a shared spindle-specific signature 
of 17 upregulated proteins involved in translation (e.g. RPL4,6,18, P3H1, PYCR1). The somatic 
mutational landscape also revealed MBCs share common TP53 mutations, and in PLEC, MUC17, 
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CRYBG2, and ZNF681. We identified that spindle and squamous MBC exhibit overlapping 
mutational profiles of genes involved in transcription, RNA metabolic processes and actin filament 
binding, while sarcomatoid tumors harbor distinct mutations in MAPK, WNT, protocadherin 
cluster genes, calcium binding and ECM organization. These data identify subtype-specific MBC 
protein profiles and mutational signatures that identified novel biomarkers for therapy. 
Three-dimensional (3D) cell culture has been widely used in recent decades, compared 
with monolayer (2D) culture, because they better mimic the in vivo state. 3D systems utilize 
different types of gels critical for their success, such as collagen or the reconstituted basement 
membrane, Matrigel, which has enabled recapitulation of tissue architecture and function that is 
more physiologic compared to 2D. However, conventional 3D models using gel-embedded 
platforms have large variability and slow transport of biomolecules to the matrix-encapsulated 
cells. Here, we developed a highly reproducible, 3D scaffold-free hanging drop method amenable 
for primary tissues including mouse and human tumors, and our analyses describe a one drop-one 
organoid format using MCF10A cells, a non-tumorigenic breast cell line. We attained high-yield 
production of uniform organoids that resemble normal human breast acini, express both mammary 
gland-specific and progenitor markers, and we developed treatment assays for EMT induction and 
neoplastic progression delivering rapid quantification of phenotypic and morphological changes. 
Integration of 3D methods with omics analyses is envisioned to enhance the study of neoplastic 
progression and generate novel targets of both MBC and TNBC tumors. 
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Chapter 1 ‒ Introduction 
 
1-1 The human mammary gland and triple-negative breast cancers 
The mammary gland is a complex structure that consists of an epithelial parenchyma situated 
in a bed of stromal cells that maintain and regulate both normal development and tumor 
progression [1], [2]. Breast cancer is the most common form of cancer in women and 
approximately 1 in 8 women in the U.S. (roughly 12%) will develop breast cancer in their 
lifetime [3]. Triple-negative breast cancer (TNBC) represents an estimated 15-18% of all breast 
cancer cases and are negative for estrogen receptor (ER), progesterone receptor (PR) or HER2 
receptor and are among the most aggressive and high grade compared to hormone receptor 
positive forms of the disease [4], [5]. Therefore, it is of paramount importance to understanding 
the underlying biology that defines the complex molecular heterogeneity within TNBCs in order 
to develop new therapies to combat it. 
The human mammary gland 
The human mammary gland is a remarkably adaptive organ that consists of a system of 
branching ducts and lobules [1]. The mammary gland has a dynamic ability to undergo cyclic 
expansions and dramatic changes in both structure and function throughout lifespan of a woman, 
including stages of development, puberty, pregnancy, lactation, and involution [1], [6]. The 
functional unit of the breast is called the terminal duct lobular unit, or TDLU, which consists of a 
duct branched into lobules, or acini [7]. Acini are the functional secretory units in the mammary 
gland containing a central lumen. The TDLU is a highly organized tree-like structure with two 
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cell layers, the epithelium and basal cell/myoepithelium surrounded by a basement membrane 
[7]. The two major cell layers composing the ducts and acinar structures are basal and luminal 
cells, however the lobular units are also composed of secretory, milk-producing cells (alveolar 
cells) [8]. Acini are lined by an inner layer of luminal cells and an outer layer of myoepithelial 
(i.e. basal) cells [9]. With respect to the entire TDLU, the normal breast tissue microenvironment 
is also embedded in an adipose-rich stroma, which contains a mixture of cell types including 
mesenchymal cells, fibroblasts, myofibroblasts, macrophages and other immune cells [2], [10]. 
The distinguishing phenotype of breast acinar architecture is maintenance of a polarized 
structure, specialized cell-cell contacts, and attachment to the basement membrane [10]–[12]. In 
addition to providing structural support, the basement membrane is known to be a crucial 
regulator of cell proliferation, differentiation and organization of normal breast tissue function, 
and is a specialized type of extracellular matrix (ECM) that contains mainly type IV collagen and 
laminin [13]. 
The pathogenesis of epithelial tumors, called carcinomas, is characterized by the disruption 
of the intact, well-ordered acinar architecture. Recent studies of oncogenic transformation in the 
mammary gland and several cell-of-origin investigations suggest that human breast cancers arise 
from cells within the TDLU [7], [13]–[15]. A hallmark feature of the oncogenic transformation is 
the loss of epithelial polarity, tissue organization, cell-cell contacts, and rupturing of the 
basement membrane. Tumor malignancy has occurred once neoplastic cells escape the basement 
membrane and begin to invade through the adjacent stroma. Histologically, invasive breast 
cancers exhibit a wide range of molecular profiles with highly heterogeneous morphologies, and 
due to this, several aspects of tumorigenesis and mammary biology are not fully understood [16], 
[17]. 
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Triple-negative breast cancer (TNBC) and current treatments 
 There are four main categories of breast cancer, these include luminal A, luminal B, 
human epidermal growth factor receptor 2 (HER2), and basal-like, as identified by studies on 
gene expression profiling [5], [6]. Triple-negative breast cancer (TNBC) represents an estimated 
15-20% of all breast cancers and they do not express estrogen receptor (ER), progesterone 
receptor (PR) or HER2 [4], [18], [19]. TNBCs are typically of high pathologic grade, exhibit 
poor long-term prognostic outcomes, and are particularly more aggressive than HER2-amplified 
and hormone-positive breast cancers. They also share molecular features such as p53 and 
prevalence of germline BRCA mutations, are highly proliferative and express a phenotypically 
basal-like and claudin-low expression pattern [20]. In addition, this basal-like phenotype has a 
hallmark expression of basal cell markers such as cytokeratin 5/6 and 17. Overall, TNBC 
exhibits a complex heterogeneity at both inter- and intra-tumoral levels and likely consists of 
several distinct molecular subgroups that have not yet been clearly elucidated.  
Emerging data highlights that TNBCs are not only very heterogeneous, but have variable 
prognosis across pathologic, genetic and clinical outcomes [21]. Central to understanding the 
prognostic significance of these outcomes, it is increasingly important to integrate pathologic, 
histologic, and other data sets together (e.g. genomics, proteomics) in order to pinpoint the 
underlying biological features, major drivers, and stage of disease. The treatment for TNBC has 
been less successful compared to other breast cancers since it lacks hormone receptor positive 
status and therefore, the use of current therapies have not been well targeted [22]. Cytotoxic 
chemotherapy has thus far been the backbone treatment option for TNBC. However, there have 
recently been encouraging results from molecularly targeted treatment options for TNBC, 
including PARP inhibitors (olaparib, talazoparib for germline BRCA mutation associated forms), 
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nab-paclitaxel for programmed death-ligand 1 (PD-L1+), and also checkpoint inhibitor 
atezolizumab [23]. As the molecular characteristics of TNBC is further revealed, a standard of 
care approach that is guided by tumor biology can be actualized as we enter a new era of TNBC 
therapeutics and management. 
1-2       Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) 
 In the last decade, there has been increasing interest in the role of epithelial-mesenchymal 
transition (EMT) and cancer stem cells (CSCs) in tumorigenesis and cancer progression. These 
two concepts are now thought to be two sides of the same coin of a broader cancer cell plasticity 
program that exists in the tumor and its associated microenvironment. EMT involves the 
transdifferentiation of cells via a change in phenotype from epithelial to the acquisition of a 
mesenchymal-like state [24]–[26]. The process of EMT plays a well-established role in 
developmental programs and embryogenesis, and occurs when the mesoderm develops multiple 
tissue types and the generation of epithelial organs such as the breast and kidney [24]. It is also 
thought that EMT-derived cells have stem cell-like properties and are also capable of undergoing 
the reverse process, mesenchymal-epithelial transition (MET) once colonization of tumor cells 
have metastasized and invaded distant sites [27]–[29]. EMT is also facilitated by key regulators 
and transcription factors such as SNAIL, SLUG, TWIST, and ZEB1 and is characterized by the 
loss of epithelial markers (E-cadherin and important cell adhesion molecules) and gain of 
mesenchymal markers (N-cadherin, vimentin, fibronectin, and cytokines like TGFβ) [29]–[31].  
Cancer cells are able to exploit this developmental EMT process during tumorigenesis 
and metastasis. However, since the cancer EMT program interacts very closely with the tumor 
microenvironment, which contains a wide range of cell types whose phenotypes are largely 
unexplored and difficult to distinguish, there has been controversy over actual molecular events 
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and clinical evidence behind EMT in cancer [32]. In addition, the presence of self-renewing cells 
in tumors, or CSCs, further complicates the situation. Cancer cell-of-origin models suggest two 
theories to explain the maintenance of malignant traits of neoplastic cells (Figure 1-1) [33], [34]. 
The first is the Stochastic Theory, which states that each cell in the tumor has the potential to 
become cancerous given the appropriate microenvironmental context. The second is the 
Hierarchy Theory, which postulates that CSCs are more likely to seed new tumors since they 
have a greater ability to self-renew compared to non-CSCs and can survive long-term as opposed 
to more mature cells, which have shorter lifespans.  
In the last 15 years, a large body of research has described a small population of cells (~ 
1%) in the tumor with evidence of self-renewal and stem-like features and are defined by their 
ability to “seed” or generate new tumors [33], [35]. Broadly, they are called “tumor-initiating 
cells” and were first discovered in the hematopoietic system and subsequently in solid tumors 
(e.g. breast, brain, colon). In fact, the discovery of hematopoietic stem cells (HSCs) 60 years ago 
has been an instrumental thrust towards elucidating a supposed CSC hierarchy [36]. In breast 
cancer, a small subset of CSCs expressing a CD44+/CD24‒/ALDH+ phenotype is suggested to be 
a putative breast cancer stem cell (bCSC) population of notable importance linked with 
metastasis [37], [38]. This has been evidenced in transplantation studies that used 
immunocompromised mice, in which a few cells were sufficient to give rise to new tumors and 
cells that were both tumorigenic and non-tumorigenic [35], [39]. Genetic lineage-tracing 
approaches also emerged, enabling the identification of stem cells in tissues in situ, but when 
interrogating bCSCs, the multipotent mammary basal cell population was found to become 
unipotent [40]–[42]. Thus, the behavior of stem cells within transplantation and lineage-tracing 
platforms was noted to differ significantly, highlighting that the variable nature of stem cell 
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marker usage depends on the context of the particular platform used, in addition to the 
microenvironmental context the stem cell resides. Such discrepancies were also observed when 
studying HSCs. Nonetheless, these findings hinted that transplantation-based methods may be 
promising for revealing potential cancer stem cells, but may not ultimately uncover the fate of 
these cells. 
To this end, recent investigations have aimed at correlating gene/protein level expression 
of EMT and/or CSC status in breast carcinomas with clinicopathological characteristics, 
molecular subtyping, and chemotherapy response to better define these phenomena in cancer. 
Because many current therapeutic options are targeted at cancer cells with conventional anti-
proliferative chemotherapies, the benefits have been limited. In the future, the full scope of the 
differentiated CSC progeny that includes identifying those quiescent or “slow-cycling” CSC 
phenotypes should be elucidated, leading to novel therapies targeting these self-renewing cells 
that are therapy-resistant.  
1-3 Metaplastic breast carcinoma 
Metaplastic breast carcinomas (MBCs) are a rare and histologically diverse form of 
breast cancer that typically presents as triple-negative breast cancer and is thought to be enriched 
in EMT and CSC properties [43]–[45]. The word “metaplastic” itself is derived from Greek and 
means “change in form.” This is due to a transformation of part or all of the tumor glandular 
carcinomatous component into a non-glandular, or metaplastic, component [46]. Although it 
accounts for roughly 1% of all breast tumors, it is present in up to 14% of breast carcinomas in 
women of African descent [47]. Metaplastic breast cancer was first documented in 1973 but only 
became recognized as a distinct histologic entity in breast cancer in 2000 [48], [49]. The 
heterologous, non-glandular elements within the carcinomatous region of MBC tumors are 
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exhibited histologically in three main forms: spindle, squamous, or sarcomatoid, in which the 
sarcomatoid also includes both osseous and chondroid differentiation [46], [50], [51]. All these 
forms are all extremely rare to arise in the breast, and compared with TNBC, metaplastic breast 
tumors are known to be more aggressive and are poorly responsive to chemotherapy. They also 
confer worse prognosis, are of higher pathological grade, and are known to have higher 
propensity for distant metastases than TNBC. Typically, these non-glandular metaplastic regions 
look like “solid nests” of tissue that are often observed next to a glandular carcinomatous region, 
such as invasive ductal carcinoma (IDC), and sometimes even ductal carcinoma in situ (DCIS) 
[43]. These findings suggest heterologous elements had initially progressed from associated 
ductal carcinoma. In addition, compared with conventional IDC patients, those diagnosed with 
MBC were shown to have less axillary lymph node involvement, and the 5-year survival rate for 
MBC is 65% compared with 89% with IDC [52].  
Due to such histologically diverse forms of MBC neoplasms as spindle, squamous or 
mesenchymal elements, there is currently a lack of available therapies that specifically target 
these different subgroups. Previously, studies have looked at the role of immunohistochemical 
markers as predictors of survival, using p53, proliferation marker Ki-67, along with ER/PR and 
HER2 status [53]–[55]. By correlating immunohistochemical expression with clinicopathologic 
parameters, several recent investigations, including from our lab, have revealed an enriched 
combinatorial EMT and CSC phenotype present across MBCs (CD44+ / CD24‒ / ALDH1A1+, 
and Ecad‒/Twist+) [56], [57]. Upon evaluation of these prognostic indicators, it has been 
observed that the combination of epithelial-mesenchymal transition markers and cancer stem cell 
overexpression are not only powerful predictors of disease-free and overall survival, but may 
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contribute to the reason why metaplastic carcinomas are particularly more aggressive than other 
TNBCs.  
Due to the imminent need to find clinical markers of MBC, the last 5 years especially has 
seen a greater push towards genomic and transcriptomic profiling studies in the hopes of 
determining the underlying molecular alterations that define each histologic subtype. At the 
genomic level to date, metaplastic carcinomas have been found to be enriched in PI3K, TP53, 
CDKN2A deletions, EGFR amplifications, and WNT, PTEN, and CTNNB1-activating mutations 
[51], [58], [59]. Notably, an increasing number of studies observed that chondroid and general 
sarcomatoid-matrix producing MBCs seem to lack PI3K aberrations [58]. Most of these are also 
commonly found in TNBC, however it is suggested that the PI3K/AKT/mTOR pathway could be 
more frequently altered in MBCs compared to TNBCs. Also, MBCs were not found to be driven 
by recurrent fusion genes, and they seem to harbor similar patterns of gene copy number 
alterations. Taken together, it has been challenging to pinpoint specific somatic mutational 
profiles that define each MBC subtype, nor do MBCs seem to be underpinned by a 
pathognomonic copy number alteration profile, and that possibly other genetic and/or epigenetic 
aberrations affecting noncoding regulatory elements share an important role and need to be 
further examined [60].  
However, a recent transcriptomic study has reported that based on RNA-based gene 
expression profiling, distinct expression patterns according to MBC histologic subtype were 
actually determined [61]. Specifically, MBCs with spindle differentiation showed distinct 
transcriptomic profiles consistent with an epithelial-mesenchymal transition profile, whereas 
chondroid and squamous differentiation were variably classified on the basis of basal-like or 
claudin-low profiles. Given this heterogeneity, and due to its rarity, it seems that future studies 
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with larger sample sizes are required to refine the boundaries of metaplastic versus non-
metaplastic carcinoma components on the basis of genomic, epigenomic, transcriptomic and 
proteomic levels.  
CCN6 (WISP3) and development of an MBC mouse model 
 To date, there is a lack of physiologically relevant animal models of metaplastic 
carcinomas. Recently, our lab has been one of the first to generate an MBC mouse model 
generated by Ccn6 deletion and a floxed Ccn6 mouse bred with an MMTV-Cre mouse [62]. 
CCN6, otherwise known as WISP3, is a secreted matrix protein of the CCN family that includes 
six members, all of which have profound regulatory roles in embryonic development, cell 
attachment and growth [63]. CCN proteins are tissue-specific and bind to cell surface receptors, 
are involved in integrin signaling, and modulate the effect of extracellular growth factors on 
epithelial cells. In addition, CCN6, located at 6q21-22, was first identified to be downregulated 
in aggressive inflammatory breast cancers, and later our lab showed that CCN6 is secreted by 
ductal epithelial cells in the breast [62], [64]. Several studies have revealed that the 
downregulation of CCN6 is linked with EMT, and thus, CCN6 was found to strongly regulate 
epithelial-mesenchymal transition and in general, any phenotypic changes between epithelial and 
mesenchymal states, and is known to modulate the TGFβ/BMP signaling axis [56], [64]. The 
Ccn6fl/fl;MMTV-Cre mice formed invasive high grade mammary carcinomas with EMT features, 
and that CCN6 expression by immunostaining was reduced specifically in the metaplastic 
component compared to both normal breast and IDC tumors. Interestingly, this mouse model 
specifically recapitulates MBCs of spindle or of mixed spindle/squamous metaplastic elements. 
Overall, Ccn6fl/fl;MMTV-Cre mouse tumors were found to have a protein expression profile 
analogous to human metaplastic carcinoma, and that Ccn6 deletion in the mammary gland is 
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sufficient to induce spindle MBCs on the basis of histological, immunophenotypic, and 
transcriptomic features. These are promising findings that could allow new targets to emerge in 
the diagnosis and management of MBC towards a subtype-specific treatement strategy. 
1-4 3D culture systems in modeling breast cancer progression 
Cell culture models are crucial for understanding biological and pathological processes 
for the evaluation of novel therapies. The literature suggests that three-dimensional (3D) culture 
systems are more physiologically relevant than conventional two-dimensional (2D) culture, as 
cells grown in a 2D environment are not capable of self-organizing and hence, tend to lose much 
of their in vivo phenotype [65]. However, when grown in 3D, cells are able to replicate 
physiological cell-ECM interactions, having been grown on an appropriate scaffold material or 
other extracellular matrix substrate that allows for a more faithful recapitulation of in vivo 
phenomena [66], [67].   Cancer cells grown in 3D also display signatures of drug resistance that 
are strikingly similar to that of in vivo tumors [68]–[70]. The use of 3D cell culture models has 
increased the understanding of breast cancer progression, enabled testing of new treatments, and 
may offer a unique platform for high throughput analyses that monitor molecular alterations 
during breast tumorigenesis, progression, and metastasis. Therefore, novel model systems that 
better recapitulate the mammary gland architecture and morphogenesis while also delivering 
reproducible quantitative parameters are greatly needed. 
3D culture of mammary cells 
Three-dimensional culture of mammary epithelial cells on a reconstituted basement 
membrane allows for the formation of polarized acini-like spheroids that resemble key aspects of 
glandular in vivo architecture. Early studies growing mammary epithelial cells in 3D found the 
main histological features of these 3D structures included a polarized morphology, cell-cell 
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contacts, and attachment to and presence of a basement membrane [10], [11], [71]. Glandular 
epithelial cells, such as in the mammary gland, require the development and maintenance of this 
polarized unit, which is critical for its function. On the other hand, the pathogenesis of mammary 
tumors requires the disruption of this highly organized architecture. Initially, studies began using 
a laminin-rich matrix, commonly known as Matrigel, or a collagen matrix, as a reconstituted 
basement membrane [69], [72]. To form acinar structures, mammary cells are typically cultured 
in a reconstituted basement membrane, Matrigel, which are derived from Engelbreth-Holm-
Swarm (EHS) tumor and is mainly composed of laminin, collagen IV and entactin and is known 
for driving morphogenetic differentiation in 3D cultures. Studies subsequently demonstrated in 
vitro mammary gland morphogenesis, mammary gland branching, and discernment of normal 
and neoplastic mammary phenotypes, including seminal works from Brugge and Bissell groups 
and others, which laid the framework for standard 3D culture procedures of breast models that 
exist today [10], [14], [73]. Several early methods implementing 3D epithelial cultures used 
certain tumor-derived cell lines like LIM 1863 (colon carcinoma cells), DU4475 (mammary 
carcinoma cells), Madin-Darby canine kidney (MDCK) cells, S2 cells, MCF-10A cells (human 
origin), primary human mammary epithelial cells (HMECs) and also mouse mammary epithelial 
cell lines like TAC-2 and EpH4 [12].  
MCF10A cells 
MCF10A, a spontaneously immortalized non-transformed human breast epithelial cell 
line, is a well-established in vitro model of the benign breast. MCF10A cells are near-diploid 
cells with stable karyotype and are derived from the breast tissue of a 36-year-old patient with 
fibrocystic changes [71], [74]. The non-tumorigenic MCF10A cells form acini with hollow 
lumen in 3D culture, which are generated either by embedding cells inside or on top of Matrigel 
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after 1-2 weeks [10]. These scaffold-based systems using MCF10A retain important features 
found in glandular epithelium in vivo and have particular advantages studying tumor initiation, 
cell-ECM biophysical interactions, migration and invasion [75]. These cells also exhibit low 
proliferative capacity, making it easy to interrogate effects of oncogenic transformations as a 
result of treatment assays, despite being cytogenetically abnormal (they harbor genetic 
abnormalities including deletion of p16 and p14ARF, and amplifications of MYC, but express 
wild-type p53). Another limitation of MCF10A as a model of normal breast function are that 
these are immortalized cells and with long-term culture, harbor loss of architectural cues of 
normal mammary cells, and despite exhibiting a central hollow lumen, MCF10A lacks multiple 
cell types such as surrounding myoepithelial cells [75]. MCF10A cells are ER‒ and associated 
with a basal epithelial phenotype, which may in turn make this cell line most relevant for 
studying triple-negative and/or basal breast cancers. Overall, mammary spheroid and organoid 
assays have provided a unique opportunity for drug development and are a promising pre-clinical 
cancer method that make it possible to interrogate the heterogenous composition of primary 
tumors. 
Hanging droplet technique 
Currently, drug development faces increasing challenges with issues of accuracy, 
sensitivity, and throughput of available in vitro testing platforms. The most common in vitro 
screening assays are still based on a monolayer, or 2D culture, which are not only the gold 
standard approach but are favored due to easy handling and better suitability for automation in 
high-throughput systems [69], [70], [76]. However, since it is known that 2D cultures lack the 
necessary physiologic and microenvironment interactions analogous to in vivo, this drastically 
limits the prediction of drug effects on humans. Therefore, there has been increasing support for 
 13 
the use of 3D cultures and particularly spheroid and organoid systems in developing high-
throughput screening assays. Consistent 3D structures are a top challenge of 3D culture methods, 
and if proven to be a scalable technique, must overcome limitations including cells that form 
slowly or have inefficient reaggregation capacity. Among these methods are the hanging drop 
technique, which allows for media exchanges and administration of chemical components with 
flexible timing [77], [78]. Others have achieved spheroid reproducibility using 96-well hanging 
drop systems, culture plate lids, spinner flask cultures, rotary cell systems, and various 
microfluidic chip devices to better control spheroid sizes, and increase spheroid formation 
efficiency [79], [80]. However, many of these platforms are tedious and produce highly variable 
spheroid sizes, are lower throughput, difficulty in handling. Microfluidics devices offer better 
consistency and simplified handling, however still suffers from compatibility with existing liquid 
handling robots, compatibility with drug screening, and long-term culturing.  
An automated, modified high-throughput 384-well hanging drop platform developed 
recently by the Takayama group have demonstrated effective and compact formation of both 
cancer cells and normal cells using the macromolecular additive methylcellulose (MethoCel), 
along with lower concentration of Matrigel to the culture media only upon cell seeding (Figure 
1-2) [81], [82]. This was found to contribute to highly uniform, compact spheroid morphologies 
and has been tested on spheroids generated from several breast cancer cell lines and MCF10A 
cells, and more recently, on primary tissues. This hanging droplet platform consists of a 384-well 
custom-made hanging drop array plate that is sandwiched between a standard Corning 96-well 
plate (Figure 1-2a-b), which is filled with distilled water and a standard plate lid. The distilled 
water from the bottom 96-well plate and the water reservoir on the two sides of the 384-well 
plate prevent evaporation of the hanging droplets, acting as a type of humidification chamber 
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(Figure 1-2c). The access holes on the top surface of the plate allow a liquid droplet containing 
live cells to be pipetted directly, resulting in consistent geometry of droplets and stable culturing 
conditions not possible using conventional flat hanging droplet substrates. Long-term culture is 
also possible, due to small volumes of droplets (~ 25 μl), allowing easier media exchanges using 
an automated liquid handling robot (Figure 1-2d) and enabling user-friendly high-throughput 3D 
culture applicable for multiple cell types and co-cultures. 
1-5 Translational application of omics technologies   
In order to extract the benefit of high-throughput studies from both in vitro (2D and 3D 
cultures) and in vivo studies (e.g. mouse models) to improve clinical outcome prediction in the 
era of precision medicine, cancer studies are now focused on omics data sets that have provided 
information regarding the etiology of oncogenesis. There is now an abundance of omics-based 
data currently available in biomedical research that has inspired the development of several 
robust statistical tools and software for interpreting and visualizing complex data sets [83], [84]. 
In addition, the complex and dynamic networks of molecular layers (e.g. genetics, epigenetics, 
mRNA, RNA, proteins, and metabolites) involved in cancer progression can be interrogated by 
omics technologies. A single omics layer can provide limited insights into the underlying 
mechanisms of disease, however, by combining these approaches obtained at different omics 
levels and assessing patterns in the cross talk between multiple molecular layers is not trivial, but 
is ultimately the goal. Therefore, the goal towards integrative multi-omics strategies may 
enhance functional analyses, discovery of key drivers contributing to specific cancers, and 
ultimately allow drug discovery, early detection, prevention and treatment at the individual 
patient level.  
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Genomics in the realm of medical research focuses on identifying genetic variants based 
on pathologic tissues, and in response to treatment. GWAS, genome wide association studies, 
made it possible from the early 2000s to map expression quantitative train loci (eQTL) for 
modeling biologic networks [85], [86]. Since then, a plethora of other omics-based technologies 
have been developed and are capable of capturing bulk information from transcripts, proteins and 
metabolites. GWAS studies generated information on multiple human populations consisting of 
thousands of individuals who have been genotyped for over a million genetic markers, finding 
statistically significant changes in minor allele frequencies and understanding complex 
phenotypes [86]. Associated techniques were also developed including genotype arrays, next-
generation systems (NGS), and whole-genome and exome sequencing [87].  
Epigenomics focuses on DNA-associated proteins such as DNA methylation and histone 
acetylation events, covalent modifications of DNA and histones, as these are considered to be 
major regulators of cell fate and gene transcription [86], [88]. Such modifications are impacted 
by genetic, heritable, and environmental factors. Several epigenome-wide association studies 
have revealed that the role of epigenetic modifications is important in disease development and 
biological processes, such as methylated regions of DNA, and certain epigenetic signatures 
known to be tissue-specific [89]. Recently established comprehensive epigenomic maps in 
multiple human tissues have emerged, such as the International Human Epigenome Consortium, 
giving insights into epigenetic modifications that correlate with disease [90].  
Transcriptomics, the molecular intermediate between DNA and protein levels, looks at 
the RNA level and measure the expression of transcripts, and allows for the identification of 
novel splice sites, and RNA editing sites [61], [91]. RNA function such as those involving 
ribosomal complexes, are also important in pathogenesis, since up to 80% of the genome is 
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transcribed but only ~ 2% actually encodes proteins [84], [91]. RNA-seq investigations have 
therefore uncovered thousands of novel isoforms that enabled the discovery of an entirely new 
field of non-coding RNA biology that has been previously overlooked [92]. For example, it is 
now clear that many noncoding RNAs, both long non-coding (lncRNAs) and microRNAs play 
critical regulatory roles in both physiologic and pathologic processes in cancer.  
At the protein level, proteomics has revolutionized the quantification of protein 
expression based on peptide abundances using mass spectrometry (MS) based methods [93]. 
These have recently been adapted for high-throughput analysis of in-depth proteomes which are 
capable of capturing thousands of proteins in human tissues and fluids. Fundamentally, MS 
methods measure the mass-to-charge ratio (m/z) of gas-phase ions, where the ion source converts 
analyte molecules into these gas-phase ions and a mass analyzer separates the ionized analytes 
based on m/z ratios [93]–[95]. The electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI) are soft ionization techniques that can ionize peptides. Four 
types of mass analyzers are commonly used in proteomics, the quadrupole (Q), ion trap (QIT), 
time -of-flight (TOF) and Fourier-transform ion cyclotron resonance (FTICR) [93]. Over the past 
decade, developments in shotgun proteomics (bottom-up methods in which peptide detection is 
used to infer proteins) and chemical labeling using isobaric tandem mass tags (TMT) and 
isobaric tags for relative and absolute quantification reagents (iTRAQ) have been used in a 
variety of clinical samples for biomarker discovery and are highly robust for hyperplexing [96]–
[98]. In addition, affinity purification which uses an antibody or genetic tag coupled with MS to 
identify associated proteins, has been widely used with chemical crosslinking and also 
previously adapted to measure interactions between proteins and nucleic acids (i.e. ChIP-seq). 
Proteomics also enables interrogation of proteins involved in post-translational modifications 
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such as phosphorylation, ubiquitination, proteolysis, glycosylation and nitrosylation, all of which 
play major roles in intracellular signaling cascades. Lastly, the field of metabolomics, which also 
uses liquid-chromatography-mass spectrometry (LC-MS) methods, has been developed to 
quantify metabolite levels from small molecules, amino acids, lipids, polar metabolites, 
carbohydrates and other products [99], [100]. Relative metabolite ratios are thought to reflect 
broad metabolic function, and some studies have even been able to use metabolomics to link 
genotype to phenotype information, and are proximal reporters of disease well-suited to serve as 
efficacy markers for drug development. 
1-6 Summary   
 Here we have reviewed a broad body of literature on triple-negative breast cancer 
progression, specifically metaplastic breast cancers and how best to model them in vitro and in 
vivo. Understanding the key drivers and signaling axes of neoplastic and oncogenic 
transformation is likely to be enabled by integrative approaches that combine information on 
multiple scales and platforms, including human patient tumors and animal model data, 3D 
organoid screening and biobanking efforts, and multi-omics data sets which analyze these 
samples on multiple molecular levels. Both TNBC and MBC are highly complex, aggressive and 
heterogeneous tumors, with a lack of understanding on the underlying pathogenesis, limited 
models of disease progression and a lack of available therapies. Especially in the case of 
metaplastic breast carcinoma, which is more aggressive and rare owing to the presence of non-
glandular components which display patterns of differentiation not typical to be found in the 
breast (spindle, squamous and sarcomatoid forms), we have introduced evidence that mouse 
models and 3D organoid platforms are capable of recapitulating key molecular drivers of such 
histological features. This makes it possible to understand the pathogenesis of this disease, how 
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these differentiation patterns arise, and what set of markers can be tested as novel therapies. 
However, in the future, studies will need to seamlessly integrate the information generated from 
animal models and 3D culture systems directly with omics technologies, which are useful for 
revealing multi-level information of thousands of genomic variants, transcripts, proteins, and 
other critical information. Pathogenesis occurs as a complex orchestration among all these 
molecular and cellular levels, resulting in the range of heterogeneity we see within these tumors, 
and it is of prime importance to collect these data sets both from large-scale and small-scale 




















Figure 1-1. Two models proposed to explain the heterogenous nature of cancer cells, the 
Stochastic Model and the Hierarchy Model (Cancer Stem Cell Theory). In the Stochastic 
Model, any cell in the primary tumor can acquire the right set of somatic mutations to develop 
and seed new tumors with self-renewal and metastatic capacity. In the Hierarchy Model, tumors 
are only initiated by a small subset of rare self-renewing cells called cancer stem cells (CSCs) 








 Figure 1-2. 3D culture platform with 384-well hanging droplet technique. a) Diagram of 384 
hanging drop culture array plate, with cross-sectional view. b) Key dimensions of the array plate. 
c) Cartoon of the final humidification chamber used to culture 3D spheroids in the hanging drop 
array plate. The 384 hanging drop array plate is sandwiched between a 96-well plate filled with 
distilled water and a standard-sized plate lid. Distilled water from the bottom 96-well plate and 
the peripheral water reservoir prevent serious evaporation of the small volume hanging drops. d) 
The 384 hanging drop array plate operated with liquid handling robot capable of simultaneously 
pipetting 96 cell culture sites [81].  (Modified from Tung et al. 2011). 
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2-1  Abstract   
Metaplastic breast carcinoma (MBC) is the most aggressive form of triple-negative cancer 
(TNBC), defined by the presence of “metaplastic” components of spindle, squamous, or 
sarcomatoid histology. The protein profiles underpinning the pathological subtypes and metastatic 
behavior of MBC are unknown. Using multiplex quantitative tandem mass tag-based proteomics 
we quantified 5,798 proteins in MBC, TNBC, and normal breast from 27 patients. MBC showed 
increased epithelial-to-mesenchymal transition and extracellular matrix, and reduced metabolic 
pathways compared to TNBC. MBC subtypes exhibited distinct upregulated profiles; translation 
and ribosomal events in spindle, inflammation and apical junctions in squamous, and extracellular 
matrix in sarcomatoid. Comparison of the proteomes of spindle MBC with MMTV-cre;Ccn6fl/fl 
spindle MBC tumors revealed a shared spindle-specific signature of 17 upregulated proteins 
involved in translation (e.g. RPL4,6,18, P3H1, PYCR1) and 19 downregulated proteins with roles 
in cell metabolism (e.g. ADH1B, ADH1C, LIPE, SOD1, FABP4). These data identify subtype 
specific MBC protein profiles providing biomarkers and therapeutic targets.  
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2-2  Introduction   
Triple-negative breast cancer (TNBC) comprise a heterogeneous group of tumors with 
varying histologies and prognosis[101]. The most lethal subtype of TNBC is termed metaplastic 
breast carcinomas (MBC), a unique and heterogeneous group that account for 0.2 ‒ 5% of all breast 
cancers[48], [49]. MBCs are characterized by the presence of a glandular epithelial component 
and a hallmark non-glandular “metaplastic” component that may consist of cells with spindle, 
squamous, and/or sarcomatoid (i.e. chondroid or osseous) features[50], [51]. Clinically, MBCs are 
more metastatic and chemoresistant than non-metaplastic TNBC, with the spindle subtype 
portending the worst prognosis[45]. This significant clinical challenge highlights the need to 
distinguish MBC tumors for diagnostic and precision treatment purposes.  
The molecular alterations that distinguish MBC from TNBC, and the protein profiles that 
determine MBC histological subtypes are poorly understood[46], [102], [103]. To date, few studies 
have investigated the genomic and transcriptomic features of MBC[59], [61], [104]. Genetically, 
MBCs have a high level of genomic instability, display a complex copy number variation pattern, 
and tend to harbor significantly more mutations in PIK3CA, WNT, and TP53 compared to TNBCs, 
as well as presenting loss of CDKN2A and overexpression and amplification of EGFR[58], [105], 
[106]. Studies have been unable to show a genetic basis among MBC histologic subtypes, but have 
recently demonstrated distinct profiles at the transcriptomic level[61]. However, little is known 
about the mechanisms of MBC metastasis, and there are no reliable biomarkers or targets of 
therapy, underscoring the need to identify protein profiles specific to MBC and subtypes. 
Our lab has generated MMTV-cre;Ccn6fl/fl knockout mice which form mammary tumors 
that recapitulate high-grade human MBC with predominant spindle components both 
morphologically and transcriptionally[107]. Using this model, we have identified an 87-gene 
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signature common between mouse and human MBCs including the transcription and translation 
regulatory proteins HMGA2 and IGF2BP2[108]. In addition, histological and 
immunophenotypical evidence suggests that MBCs are enriched in epithelial-to-mesenchymal 
(EMT) and different cellular compartment express stemness markers[37], [44], [57]. However, the 
protein profiles of human and mouse MBC are unknown. 
Few proteomics studies to date explore invasive breast carcinoma signatures, with very 
limited information on MBC and normal tissue counterparts[18], [19], [109]. Here, we used human 
tissue samples of MBC, TNBC and normal breast and a quantitative custom-built platform to test 
the hypothesis that the histological subtypes of MBC may have distinct protein profiles that may 
result in the pathological phenotypic diversity and aggressive clinical behavior. We employed 
tandem mass tag (TMT) based proteomics technology and a novel Philosopher/TMT-Integrator 
computational pipeline that our group has recently developed and optimized for the analysis of 
large patient cohorts, to process the acquired mass spectrometry data. By unravelling the protein 
signatures within MBC and their relationship to TNBC and normal breast tissue, our study 
advances the understanding of the biology of MBC and provides potential diagnostic and 
prognostic markers, as well as testable targets of therapy specific to MBC pathological subtypes.   
 
2-3  Methods   
Tissue samples and histology and pathological evaluation 
We employed frozen tissue samples from 14 women with MBC and adjacent normal tissues 
from the surgical pathology files at Johns Hopkins University, 6 TNBC and corresponding 
adjacent normal tissues from the surgical pathology files at the University of Michigan, with IRB 
approval. Each specimen was collected 30 minutes after operation and immediately transferred to 
 24 
sterilized vials, snap frozen in liquid nitrogen and stored at ‒80 C. Tumors were diagnosed 
according to the World Health Organization (WHO) classification into the following groups: 
spindle, squamous, and sarcomatoid (chondroid and/or osseous) MBC. Other pathological and 
clinical features such as estrogen and progesterone receptor analysis, Her2/Neu expression, Ki-67 
proliferation index, tumor grade, tumor size, lymph node and distant metastasis were recorded in 
surgical pathology reports. At the time of sample preparation, we cut a representative 0.5 cm piece 
of each of MBC, TNBC and normal sample, which was embedded in paraffin, sectioned to 5 μm 
and stained with hematoxylin and eosin stained (H&E) for diagnosis confirmation.  
Sample Preparation  
Frozen specimens were kept on dry ice and cut to approximately 50 mg of tissue from each 
sample to be used for proteomic analyses. Specimens were diced and mechanically dissociated 
with a scalpel and placed in labeled 1.5ml Eppendorf tubes containing three stainless steel 
microbeads. Tubes were then submerged in liquid nitrogen for 60 seconds and immediately 
homogenized using a mixer mill (Retsch MM400) for 2-3 cycles at maximum speed (30 Hz 
vibrational frequency) at 60 seconds per cycle. If any tissue had not been homogenized, another 
cycle was repeated. Samples were then placed on ice and 495 μl of RIPA buffer and 5 μl protease 
inhibitor were added to each tube, resuspended, and placed on a rocker for 30 min on ice at 4C. 
Beads were removed from tubes with a magnet and samples were ultrasonicated and centrifuged 
at 14,000 rpm for 30 minutes at 4C. The supernatant was collected to retrieve a desired 2 mg/ml 
of protein, followed by standard protein quantification methods and storage at ‒80 C. 
Protein extraction and TMT labeling procedure  
Tandem mass tag (TMT) labeling was performed for mass spectroscopy (MS) using three 
consecutive TMT-10plex isobaric labeling kits (ThermoFisher, Cat #90111) according to the 
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manufacturer’s protocol. A master mix containing equal amount of protein from each of the 
twenty-seven samples was generated. 60 μg of protein from each sample and the master mix were 
reduced with DTT (5 mM) at 45 C for 1 hr followed by alkylation with 2-chloroacetamide (15 
mM) at room temperature (RT) for 30 min. Proteins were precipitated by adding six volumes of 
cold acetone and incubating overnight at ‒20 C and pelleted by centrifuging at 8000 x g for 10 
min at 4 C. Supernatants were discarded and pellets resuspended in 100 μl of 100 mM TEAB, 
digested overnight at 37 C by adding 1.1 μg of sequencing grade modified porcine trypsin 
(Promega, V5113). TMT reagents were reconstituted in 40 μl of anhydrous acetonitrile and 
digested peptides transferred to the TMT reagent vial, and incubated at RT for 1 hr. TMT channels 
for each of sample are given in Table 2. The reaction was quenched by adding 8 μl of 5% 
hydroxylamine and incubating for 15 min. For each of the three TMT experiments, 9 samples and 
1 master mix (Table 2) were combined, dried, followed by 2D separation, with the first dimension 
containing an aliquot from each sample mix (100 μg) underwent fractionation using high pH 
reverse phase fractionation kit (following the manufacturer’s protocol, Pierce). Fractions were then 
dried and reconstituted in 10 μl of loading buffer, 0.1% formic acid and 2% acetonitrile.  
LC-MS/MS analysis 
For data acquisition, an Orbitrap Fusion (ThermoFisher) and RSLC Ultimate 3000 nano-
UPLC (Dionex) was used to obtain raw data. To increase accuracy and confidence in protein 
abundance measurements, a multinotch-MS3 method was employed for MS data analysis. 2 μl 
from each fraction were resolved in 2D on a nanocapillary reverse phase column (Acclaim PepMap 
C18, 2 micron, 75 μm i.d. x 50 cm, ThermoFisher) using a 0.1% formic/acetonitrile gradient at 
300 nl/m (2-22% acetonitrile in 150m, 22-32% acetonitrile in 40m, 20 min wash at 90% followed 
by 50 min reequilibration) and directly sprayed onto Orbitrap Fusion with EasySpray 
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(ThermoFisher; Spray voltage (positive ion) = 1900V, Spray voltage (negative ion)= 600V, 
method duration= 180min, ion source type =NSI). The mass spectrometer was set to collect the 
MS1 scan (Orbitrap; 120 K resolution; AGC target 2x105; max IT 100 ms), and then data-
dependent “Top Speed” (3 s) MS2 scans (collision induced dissociation; ion trap; NCD 35; AGC 
5x103; max IT 100 ms). For multinotch-MS3, the top 10 precursor ions from each MS2 scan were 
fragmented by HCD followed by Orbitrap analysis (NCE 55; 60 K resolution; AGC 5x104; max 
IT 120 ms; 100-500 m/z scan range). 
Data analysis and protein quantification  
Raw MS data were converted using msconvert in Proteowizard software suite[110] to 
mzML format. MS/MS spectra were searched using the MSFragger (v20181128) database search 
tool[111] against UniProt human protein database (UP000005640, last modified 2018-12-13; 
73,928 proteins), appended with an equal number of decoy sequences and common contaminants. 
MS/MS spectra were searched using the following criteria: precursor-ion mass tolerance of 20 
ppm, fragment mass tolerance of 0.6 Da (C12/C13 isotope errors (-1/0/1/2/3)), where cysteine 
carbamylation (+57.0215) and lysine TMT labeling (+229.1629) were specified as fixed 
modifications, and methionine oxidation (+15.9949), N-terminal protein acetylation (+42.0106), 
and TMT labeling of peptide N-terminus and serine residues were specified as variable 
modifications. The search was restricted to fully tryptic peptides, allowing up to two missed 
cleavage sites. MSFragger output files were processed using Philosopher toolkit (v20181128, 
github.com/Nesvilab/philosopher) as follows: The search results were first processed with 
PeptideProphet[112] (high-mass accuracy binning, semi-parametric mixture modeling options); 
ProteinProphet[113] was used to assemble peptides into proteins (protein inference) to create a 
combined file of high confidence proteins. Protein groups were filtered to 1% false discovery rate 
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(FDR) using the target-decoy strategy and the best peptide approach[98], [114], picked FDR 
adjustment[115]. The individual PSM lists for each TMT 10-plex we assembled, with peptides 
assigned either as a unique peptide to a particular protein group or assigned as a razor peptide[116] 
to a single protein group that had the most peptide evidence, and additionally filtered to 1% PSM-
level FDR. For PSMs passing these filters, MS1 intensity of the corresponding precursor-ion was 
extracted using the Philosopher label-free quantification module based on the moFF method (10 
ppm mass tolerance and 0.4 min retention time for extracted ion chromatogram peak tracing)[117]. 
For all PSMs corresponding to a TMT-labeled peptide, 10 TMT reporter ion intensities were 
extracted from the corresponding MS3 scans (using 0.002 Da window) and precursor ion purity 
scores were calculated using the intensity of the sequenced precursor ion and that of other 
interfering ions observed in MS1 data (within 0.7 Da isolation window). 
Normalization and quality control  
Three PSM tables from each TMT-10plex experiment generated as Philosopher output files 
were used as input to TMTIntegrator (v1.0.0; github.com/huiyinc/TMT-Integrator) for 
normalization and generation of integrative reports at the gene and protein level. For best 
quantitation quality, we only included PSMs (unique and razor peptides) that passed the following 
criteria: TMT label and quantification in the reference sample exist, minimum peptide probability 
0.9, precursor ion purity >= 50%, minimum MS1 intensity 0.05%, summed MS2 intensity >= 5%. 
PSMs mapping to common contaminants were excluded, and for redundant PSMs, a single PSM 
of highest summed TMT intensity was kept. Then, intensities in each TMT channel were log2 
transformed, and the reference channel intensity (pooled reference sample) was subtracted from 
that for the other nine channels (samples), thus converting the data into log2-based ratio to the 
reference scale. Here, the master mix TMT channel (131) was used as the reference channel. PSMs 
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were grouped by the corresponding gene/protein, and outlier removal using the interquartile range 
(1.5 IQR) algorithm was applied.  
The gene-level median was calculated from the remaining PSM ratios, and then normalized 
using the median absolute deviation (MAD), given the p by n table of ratios for entry j in sample 
i, Rij, the median ratio Mi  = median(Rij, j=1,…,p), and the global median across all n samples, M0 
= median(Mi, i=1,…,n). The ratios in each sample were median centered, R
C
ij = Rij – Mi. The 
median absolute deviation of centered values in each sample was calculated, MADi = 
median(abs(RCij), j=1…p), along with the global absolute deviation, MAD0=median(MADi, 
i=1,…,n), and scaled to derive the final normalized ratios: RNij = (R
C
ij/ MADi) × MAD0. Finally, 
normalized ratios were converted back to the absolute intensity scale using the estimated intensity 
of each entry in the reference sample. The reference intensity was estimated using the weighted 
sum of MS1 intensities of the top 3 most intense peptide ions [118], and in computing REFi = 
mean(REFik, k = 1,…,q), missing intensity values were imputed with a global minimum intensity 
value. The final abundance (intensity) of entry i in sample j (log2 transformed) was computed as 
Aij = R
N
ij  + log2(REFi). 
Missing data imputation 
Upon inspection, experiments 1, 2, and 3 contained 18%, 14%, and 12% missing values, 
respectively. For missing data imputation, we used the multivariate imputation by chained 
equations algorithm using the statistical software ‘mice’ package (v3.4.0) in R is a gold standard 
method of choice to handle missing data and has been reported to produce lower estimate error 
rates compared to other methods (e.g. K nearest neighbors or singular value decomposition). We 
used the following input parameters: m=5 (number of imputed data sets), method=’pmm’ 
(predictive mean matching), and maxit=50 (number of iterations). Rubin’s Rules (Rubin 1976 and 
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1987) were applied to pool estimates using logistic regression modeling. For statistical 
performance, we used significance testing of the categorical variables (i.e. patient expression 
values) to generate a covariance matrix containing pooled regression coefficient estimates, 
standard errors of parameter estimates, and p-values. We derived a pooled p-value < 1.6E-03 using 
the median p-value from the significance tests. The computational details are described in the 
original Rubin-Barnard approach[119]. 
Statistical analysis and subtyping of MBC 
The batch corrected, imputed, combined data matrix was loaded and unsupervised PCA 
clustering was performed in R (v3.4.0) using standard k-means algorithms (e.g. Bayesian, 
Silhouette, Elbow) for finding optimal clusters, Cluster 3.0 was used for hierarchical clustering 
(median centering, uncentered correlation, and complete linkage), and visualization of results 
using Java Tree View (1.1.6r4). For differential expression analysis between tumors (MBC, 
TNBC) and normal samples, where data for each patient subgroup (e.g. spindle, triple-negative, 
normal) were pooled and results averaged, fold change was calculated by subtraction of averaged 
tumor subgroups to averaged control, and a Student’s t-test was used to estimate -log10p-value. 
Proteins within a statistical region of FC>1 and p<0.05 were considered for analysis, including all 
proteins with FC>2 and p<0.01. For enrichment analyses, we performed gene ontology (GO) over-
representation tests (GO annotations: biological process, molecular function, cellular 
compartment, protein domain) in PANTHER (v14.1), and STRING (v11.0) database for 
confirming enrichment results with topological features from protein-protein interaction networks 
among subgroups. For patient stratification tests, one-way ANOVA statistical analysis was 
performed between multiple groups and p<0.05 was considered significant. 
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Gene set enrichment analysis (GSEA)  
GSEA is an aggregate score and running-sum statistic approach that enables molecular 
signature based statistical significance testing that considers the entire gene set containing a ranked 
list of all expression values in a data set without requiring a cutoff of differentially expressed 
values for functional analysis (Mootha et al., 2003; Subramanian et al., 2005).  We supplied a pre-
ranked list of two classes, up- and downregulated fold change values for each subgroup to be 
analyzed (MBC vs. TNBC, and across MBC subgroups: Spindle vs Squamous, Spindle vs 
Sarcomatoid, and Squamous vs. Sarcomatoid). To understand functional enrichment profiles of 
the proteomics results, we used annotated gene collections downloaded from the Molecular 
Signatures Database (MSigDB v7.0 for “H” (hallmark gene sets), “C2” (curated gene sets), and 
“C5” (GO gene sets). We determined normalized enrichment scores (NES) with the total protein 
list as background, and the following parameters: n=1000 permutations, where p-adjust < 0.05, 
and FDR < 0.05 were considered significant. The GSEA analysis was performed using the 
clusterProfiler and fgsea package in R and loading gene set collections from available gmt files 
from the BROAD Institute according to GSEA documentation (Subramanian, Tamayo 2005, 
Liberzon 2011).  
Whole-exome sequencing (WES)  
DNA samples with matched tumor and healthy counterparts from 10 pairs of samples in 
our patient cohort was subjected to whole exome sequencing using the NovaSeq 6000 Illumina 
system at the University of Michigan Advanced Genomics Core Facility in 150 bp paired-end 
format. Libraries were prepared used the NEBNext Ultra 2 FS DNA library prep kit for Illumina 
(NEB #E7805S; New England BioLabs) with 100ng DNA input, 15 min fragment, 275-475 bp 
size selection and 6 PCR cycles. Samples were captured with the IDT xGen hybridization capture 
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kit using 174ng of each library pooled for capture and a final PCR of 7 cycles. Fastq generation 
was performed using Illumina’s bcl2fastq software version 2.20.  
WES analysis and pathway enrichment  
The exome sequencing data was analyzed by the variant calling pipeline developed by the 
University of Michigan Bioinformatics Core. FastQC v0.11.7 was used to assess the quality of raw 
reads, which were trimmed to remove Illumina adapters and low quality ends using Trimmomatic 
v0.39, aligned to the hg38 reference genome using BWA v0.7.17, followed by removal of 
sequence duplicates, SAM tag fixing, local realignment around INDELs, base quality score 
recalibration and target coverage summarization using GATK v4.1.4.0 or v3.8 (for indel 
realignment only). Normal-Tumor paired alignment files were submitted to GATK's MuTect2, 
Varscan v2.4.4, and Strelka v2.9.10 for the detection and filtration of somatic variants. Only the 
somatic variants on the canonical chromosomes that passed each caller's quality filter were kept. 
For Mutect2, variants were first called from the normal samples and a panel of normals (PoN) was 
created and used for somatic variant calling. Cross-sample contamination and orientation bias were 
estimated and used for variant filtration. For VarScan, an alignment coverage file was first created 
using SAMtools v1.5 from the pair of normal and tumor samples together, and then used for 
somatic variant calling. The selected high-confidence somatic variants were filtered using 
VarScan's fpfilter after allelic read counts were calculated using bam-readcount v0.8. For Strelka, 
structural variant/INDEL candidates were first called using Manta, as recommended by Strelka 
manual as a best practice.  
Candidate variant calls across all samples and patients were merged using Jacquard v1.1.2 
and included all variant loci whose filter field passed in MuTect2 or Strelka or VarScan (VarScan 
calls were limited to high confidence somatic variants confirmed in false-positive filter). Allele 
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frequency (AF) parameter from Strelka was calculated by Jacquard based on the allelic read depth 
reported by Strelka since Strelka does not report AF directly. Jacquard inferred consensus 
genotype (GT), and calculated average alternate allele frequency (AF), from individual caller’s 
calling results. Variants were annotated using VarSeq v1.4.3. Variants excluding intergenic 
variants and common SNPs (SNPs whose allele frequency is higher than 5% in 1000 Genomes 
Phase 3 dataset) were integrated to create a gene-level variant and effect summary table using 
GeneRollup v0.3.2 (see additional files). Before filtering was applied, there were 11,652 total 
variants including those that fell in low complexity genomic regions, common SNPs, and 
duplicated regions. After filtering only out low complexity genomic regions, there were 980 total 
variants. 
For enrichment analyses, gene lists of somatically mutated genes were generated for each 
MBC subtype and subjected to GO and pathway (KEGG, Panther, or Reactome) enrichment 
analysis using the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt 2019, Liao, Zhang 2019). 
We applied BH correction, at least three genes per pathway, p-adjusted < 0.05 as significantly 
enriched, and used the human genome as the reference set.  
Data Availability 
All mass spectrometry proteomics data were deposited to the ProteomeXchange 
Consortium through the PRIDE partner repository. 
2-4  Results   
Human samples and clinical data 
To elucidate the proteomic profile of MBC and understand the differences in protein 
expression with TNBC and normal breast tissues, we assembled a clinical cohort of 15 frozen 
MBC which were classified clinically according to their predominant metaplastic component into 
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the following subtypes: spindle (n=6), squamous (n=4), and sarcomatoid (n=5). In addition, we 
included 6 non metaplastic TNBCs and 6 normal adjacent breast tissues (Table 1 and Fig. 2-1a). 
All patients were women with a mean age of 55 years old (range 33 to 89 years old). The majority 
(14 of 15, 93.33%) of MBC and all TNBC were of histological grade 3, and all were negative for 
estrogen and progesterone receptor, and for HER2/neu overexpression. Of the 15 MBC, 11 
(78.6%) were stage I/II and 3 (21.4%) stage III/IV at the time of diagnosis. Of the 6 TNBC, 5 
(83.3%) were stage I/II and 1 (16.6%) stage III at diagnosis. At follow up, 4 of 14 (28.6%) MBC, 
and 1 of 6 (16.66%) TNBC developed distant metastasis to the lungs, liver, skin, and bone.  
The proteome of metaplastic breast carcinoma 
We leveraged the increased throughput of multiplexed TMT 10-plex proteomics and our 
automated and robust computational data analysis pipeline to generate a quantitative proteome 
profile of 27 human tissue samples (Fig. 2-1b). We arranged the samples into three experimental 
groups appropriate for the 10-plex TMT isobaric labeling strategy (n=10 samples per experiment; 
9 tissue samples and 1 reference sample consisting of a pool of all 27 tissues) (Table 2). The three 
proteomic TMT 10-plex experiments identified 82,251, 84,667 and 84,386 peptides, respectively, 
to a depth of 5,798 unique proteins across all samples (1% protein and 1% PSM false discovery 
rate). We used the MSFragger and Philosopher tools (v20181128, 
github.com/Nesvilab/philosopher) for peptide identification, protein inference, FDR filtering, and 
extraction of quantification information form raw data, and TMT-Integrator for additional quality 
assessment and filtering, PSM selection, outlier removal, peptide-to-protein quantification roll-up, 
and normalization (Fig. 2-1b). We performed a gold standard data imputation method using the 
multivariate imputation by chained equations (“mice”)[119] package in R, to preserve statistical 
power and sample size by producing unbiased estimates of the missing values. Next, we performed 
 34 
standard batch correction in R, and the resulting expression matrix was used for all downstream 
analyses (Fig. 2-2).  
Among the 5,798 proteins found in the MBC proteome, 5,635 unique proteins passed 
through quality filters in the TMT-Integrator algorithm, consistent with each sample. The 
distribution of all patient samples and principal component analysis (PCA) shows a clear 
distinction between normal breast and tumor proteomes (Fig. 2-3a). Unsupervised k-means 
clustering methods between MBC and TNBC proteomes and hierarchical clustering demonstrates 
modest distinction of MBC subtypes and TNBC, the latter overlapping most with spindle and 
squamous MBC (Fig. 2-3b, Fig. 2-4). In addition, 1 of the 15 MBC samples was excluded from 
downstream analyses since it was confirmed by histology and proteomics that the piece cut for 
analysis contained only normal tissue. 
General features of the MBC proteome relative to normal tissues demonstrate a global 
downregulation program involving major tumor suppressors, extracellular matrix activities, and 
wound healing responses according to the clustering analysis (Fig. 2-3b), while enrichment 
analysis revealed the top GO molecular function for upregulated MBC proteins was procollagen-
proline dioxygenase activity, and aldehyde dehydrogenase activity for downregulated proteins 
(Fig. 2-5). The MBC proteome establishes with functional relevance that MBC tumors and normal 
tissues have distinct protein profiles and exhibits deregulation of novel tumorigenic pathways.  
Differential expression analysis of MBC proteome relative to TNBC and within MBC 
subtypes  
Next, we sought to test the hypothesis that MBC histopathological subtypes are associated 
with specific proteomic signatures. We grouped patient samples according to histological MBC 
subtypes, where samples with mixed features were grouped in the subtype belonging to their 
 35 
dominant feature (i.e. squamous with partial spindle features was grouped to squamous subgroup), 
and performed differential expression analysis of MBC relative to TNBC, and across MBC 
subtypes (Fig. 2-6). Compared to TNBC, MBC shows deregulation of the immune system 
(humoral immune responses; p<1-e04) and extracellular structure organization. Our analyses also 
revealed distinct functional processes among MBC subtypes, such as enriched keratinization 
(epidermal and keratinocyte differentiation) in squamous, regulation of proteolysis and protein 
activation cascade in spindle, and leukocyte activation and exocytosis in sarcomatoid.  These 
results reveal common as well as distinct cellular differentiation profiles within the MBC 
proteome.  
To gain a better understanding of the functional differences within MBC pathological 
subtypes and elucidate potentially unique protein signatures, we applied gene set enrichment 
(GSEA) analysis from the molecular signature database (MSigDB) using hallmark (Fig. 2-7), 
canonical pathways (Fig. 2-8) and GO gene sets (Fig. 2-9). Compared to TNBC, the top 
upregulated hallmark across MBCs is epithelial-to-mesenchymal transition (EMT) while oxidative 
phosphorylation is the top downregulated hallmark pathway (Fig. 2-7). 
GSEA hallmark analyses revealed distinct up- and downregulated protein profiles among 
MBC subtypes (Fig. 2-7), and GSEA enrichment plots helped delineate specific differences in top 
pathways (Fig. 2-10). Comparison within pathological subtypes showed that spindle MBC has 
high MYC and E2F targets, and ribosome pathway proteins (KEGG pathways; Fig. 2-8), 
squamous MBC has high interferon gamma (and broad inflammatory responses), P53 and PI3K 
signaling, apical junction, and low OXPHOS, MYC and E2F targets, while sarcomatoid MBC has 
high EMT and OXPHOS, and low interferon gamma, MTORC1, and PI3K signaling (Fig. 2-7 and 
2-10). Visualization of top enriched up- and downregulated terms and their associated proteins are 
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shown by protein networks (Fig. 2-11) which can be investigated as potential therapeutic 
candidates. These up- and downregulated protein signatures were further validated by additional 
differential expression analyses of each MBC relative to TNBC (Fig. 2-12). Together, these 
analyses pinpoint specific pathways operating in MBC compared to TNBC, and highlight MBC 
subtype specific pathways. 
 
Patient stratification analysis: personalized signatures in MBC and TNBC tumors 
To extend our proteomics approach to the individual patient level, we carried out 
differential expression analysis on hallmark pathways and makers of molecular subtypes in each 
tumor. Stratification of patient protein profiles demonstrate upregulation of EMT and cancer stem 
cell (CSC) proteins across MBC subtypes and TNBC, coupled with downregulation of 
stromal/stem cell proteins and endothelial-to-mesenchymal transition (EndMT; CDH5, IGFBP4, 
CD34) (Fig. 2-13). Stratification of patient protein profiles according to the expression of claudins, 
basal, and luminal proteins shows that spindle MBC is claudin-low, basal-low, and luminal-low, 
squamous MBC is claudin-low, basal-high, and luminal-low, sarcomatoid is claudin-low, basal-
variable, and luminal-low, and TNBC is claudin-variable, basal-low, and luminal-high (Fig. 2-
13b). These results show that a combination of claudins, basal, and luminal markers are able to 
stratify individual patient’s tumors and may be useful for personalized strategies. 
Patient-stratified differential expression analysis according to expression of our recently 
identified MBC markers, HMGA2 and IGF2BP2[108] shows that they are concordantly 
upregulated in spindle MBC (Fig. 2-13c). These data provide evidence that patient-stratified 
analyses distinguish MBC subtypes, and provide independent validation for using HMGA2 and 
IGF2BP2 diagnostically and as a therapeutic opportunity for spindle MBC.   
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Whole exome sequencing within human MBC and subtype-specific mutational signatures  
Based on our discovery of subtype-specific hallmark protein pathways in MBC, we set out 
to elucidate the hypothesis that each pathway may exhibit distinct DNA mutational profiles. Out 
of the 15 MBC tumors, 10 pairs of tumors with their normal tissue counterparts passed initial 
quality control for whole exome sequencing (Fig. 2-14). Most of the variants observed were 
intronic (Fig. 6a), and when filtering only missense and loss-of-function or “LoF” (Fig. 6b), we 
found that MBCs shared frequent somatic mutations in TP53 (70%), MUC17 (60%), PLEC (30%), 
CRYBG2 (40%), and ZNF681 (30%) (Fig. 2-14c).  Spindle and squamous shared AHNAK 
mutations (AHNAK, AHNAK2 (80%) in spindle; AHNAK (33%), AHNAK2 (67%) in squamous) 
and in PI3K genes (PIK3C2A (20%) in spindle; PIK3CA (33%) in squamous). Squamous MBC 
also harbored mutations MTOR, NOTCH3, and PTEN (33%). Sarcomatoid MBC shows genetic 
alterations in cadherin, calcium ion and WNT signaling, with frequent mutations in the 
protocadherin gene cluster (PCDH family), and CDH7, MAP3K2, and FAT1 (50%) (Fig. 2-14b 
and e). In addition, allele frequencies are similar for variants across MBC subtypes (Fig. 2-14d). 
Taken together, these data show that MBCs share mutations in five genes, with only TP53 having 
been reported previously [54], [55]. These data also reveal that sarcomatoid MBC has a distinct 
mutational profile from spindle and squamous MBC, highlighting the importance of the 
proteomics landscape in distinguishing MBC pathological subtypes, which paves the way for 
mechanistic and functional studies elucidating the biology of these tumors.  
 
Comparison of human MBC with MMTV-Cre;Ccn6fl/fl MBC mouse model defines a protein 
signature of spindle MBC 
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To further refine the protein landscape of spindle MBC and determine common deregulated 
proteins between human and mouse tumors, we performed quantitative proteomics on MMTV-
Cre;Ccn6fl/fl spindle MBC tumors followed by comparison with human MBC proteomes (Fig. 2-
15a-b, Fig. 2-16). Compared to normal mouse mammary glands, MMTV-Cre;Ccn6fl/fl spindle 
MBCs showed increased MYC, E2F, unfolded protein response and ribosomal pathway proteins, 
which are similar to human spindle MBC (Fig. 2-7).  
Based on shared pathology, metastatic ability, and hallmark pathways, we hypothesized 
that human and mouse spindle MBC may have an overlapping protein signature. Enrichment 
analyses in GO annotation and STRING databases uncovered a set of 36 proteins, 17 upregulated 
and 19 downregulated that overlapped between human and mouse spindle MBC proteome (Fig. 2-
15c). The shared downregulated proteins have roles in metabolic processes including oxidation-
reduction, carboxylic acid and ethanol metabolism (e.g. ALDH1L1, ADH1B, ADH1C, SOD1, 
LIPE, FABP4). Among the upregulated proteins are those involved in ribosomal function, 
translation, and RNA metabolism (e.g. RPL18A, RPL18, RPL6). In addition, we found a highly 
enriched protein-protein interaction network among the upregulated proteins (p < 1e-16). 
Together, these data delineate significantly deregulated pathways in spindle MBC in human and 
mouse tumors and nominate a subset of proteins that may be useful markers and targets of therapy. 
 
2-5  Discussion   
Here we present a quantitative proteomic landscape of human MBC, a subtype of TNBC 
with a defining histology, frequent chemoresistance, and distant metastases[120]. Using tissue 
resources from patients and from an MBC spindle mouse model, robust proteomics and novel 
bioinformatics tools we demonstrate shared and subtype-specific altered proteomes present in 
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spindle, squamous and sarcomatoid MBC, providing insights into the biology of this aggressive 
form of breast cancer and offering opportunities for precision medicine.  
Despite the impact of protein expression on tumor phenotypes and clinical behavior, our 
knowledge on the protein landscapes of human breast cancer, and how differential profiles 
contribute to breast cancer phenotypes is very limited.  Recent advances in proteomic technology 
and bioinformatics have enabled detailed characterization of breast cancer[19], [95]. However, 
studies to date have focused on frequent subtypes of breast cancer, with few to no MBC cases and 
normal breast tissues.   
Upon in depth cross-analyses of MBC to both TNBC and normal tissues, and between each 
MBC subtype using GO and MSigDB databases, we uncovered common and subtype-specific 
differences among MBCs and their relationship with TNBC. Compared to TNBC, the proteome 
of MBC has a highly enriched EMT phenotype, with increased inflammatory responses (mainly 
in spindle and squamous), an active ECM, and reduced oxidative phosphorylation. These data are 
consistent with our previous studies showing that MBC express proteins involved in the EMT 
process, which may contribute to a more stem-like and aggressive phenotype than TNBC, and with 
transcriptome studies showing that MBCs cluster as basal-like and claudin-low.[57], [121] 
Subtype-specific proteins and pathways emerged when we compared proteomic profiles of 
spindle, squamous and sarcomatoid tumors. A salient feature of spindle MBCs, which are highly 
proliferative and exhibit pathological evidence of EMT with elongated cancer cells, is upregulated 
expression of E2F and MYC pathway proteins, ribosomal proteins and transcriptional and 
translational events. These findings are intriguing based on data showing that E2F and MYC are 
key drivers of cancer cell proliferation and EMT processes, where ribosome biogenesis and 
increased translation play an essential role.[122], [123] These data also suggest that spindle MBC 
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have a deregulated balance between translation and metabolic pathways which needs to be further 
investigated  
Our data show that squamous MBC has upregulated inflammatory responses (e.g. IFN-γ, 
TNFα, PI3K/MTOR), keratinization, and widespread cell adhesion marker expression (e.g. apical 
junction, adherens, CAMs and cytoskeleton proteins), and decreased oxidative phosphorylation, 
MYC and E2F pathways relative to other MBC subtypes. On the other hand, sarcomatoid MBC, 
which includes chondroid and osseous differentiation, exhibit a predominance in extracellular 
matrix signaling cascades and an amplified EMT program, increased oxidative phosphorylation, 
and decreased inflammatory responses compared to both spindle and squamous subtypes, likely 
owing to its differentiation along mesenchymal lineages[124]. Also, we observed that in general, 
there is no significant difference in P53 and PI3K pathway between MBCs and TNBC. 
Collectively, our proteomic analysis suggests that while spindle, squamous and sarcomatoid 
MBCs and TNBC may share initial neoplastic events, each MBC subtype appears to have unique 
and active differentiation programs. 
MBC are chemoresistant and metastatic, but the underlying molecular events and driver 
pathways are unclear. Further, there are no effective treatments against these tumors.[48], [52] The 
heterogeneity of MBC has been investigated at the genetic level[58], [60], [125], however the 
relationship between genomic alterations with proteomic profiles is unknown. While MBC were 
reported to harbor somatic mutations in TP53, PI3K/MTOR and Wnt signaling pathway genes,[60] 
no subtype-specific mutational profiles in MBCs have been shown to date. Our whole exome 
sequencing analyses of 10 paired tissue samples of MBC and normal breast tissue from the same 
patients identified somatic mutations common to all MBCs in five genes; TP53 in 70%, MUC17 
in 60%, CRYBG2 in 40%, PLEC in 30%, and ZNF681 in 30%. Of these, mutations in MUC17, 
 41 
CRYBG2, PLEC and ZNF681 have not previously been reported in MBC. We found that while 
spindle and squamous MBC exhibit overlapping mutational profiles of genes involved in 
transcription, RNA metabolic processes and actin filament binding, sarcomatoid tumors harbor 
distinct mutations, especially in MAPK, WNT, protocadherin cluster genes, calcium binding and 
ECM organization. Taken together, these results demonstrate novel somatic mutations in MBC 
tumors, distinct mutational profiles of sarcomatoid MBC compared to the overlapping landscape 
of spindle and squamous tumors. These data underscore the relevance of elucidating the proteomic 
landscape to nominate subtype-specific proteins and pathways, especially between tumors with 
spindle and squamous differentiation, that may lead to treatment targets. 
Quantitative proteomics of our model of spindle MBC MMTV-Cre;Ccn6fl/fl tumors 
demonstrated a significant overlap with human spindle MBCs, with shared enrichment in E2F, 
MYC, EMT, and ribosomal proteins. Our analyses further pinpoint a set of 36 proteins commonly 
deregulated in mouse and human spindle MBCs which have not been previously considered in 
these tumors. The 19 downregulated proteins have functions in metabolic processes, while of the 
upregulated the majority are ribosomal proteins, and those involved in transcription and 
translation. Together these data validate the MMTV-Cre;Ccn6fl/fl model as a useful tool to 
investigate and test new therapeutic targets for spindle MBC, and nominate a set of significantly 
deregulated proteins and pathways as therapeutically operable targets. Our studies may pave the 
way towards mechanistic and functional investigations of these proteins in the biology of spindle 
MBC.  
In addition to subtype-specific tumor signatures, our patient stratification analysis 
uncovered a stromal cell expression pattern in MBCs, with the most prominent being 
downregulated expression of mesenchymal stem cell proteins (CD59, CD248), macrophages 
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(CD209), immune cells (CD8A), hematopoietic stem / endothelial progenitors / macrophages 
(CD34, CD36, CDH5), a recently discovered mammary stem cell marker (CDH5)[126], and we 
detected evidence of endothelial-to-mesenchymal transition (EndMT; CDH5loIGFBP4loCD34lo). 
The stromal profile is intriguing and has not been previously considered in MBC. Furthermore the 
identification of downregulated EndMT proteins is intriguing, as this process[127] has not  been 
previously considered in MBC. These findings lead to the hypothesis that downregulation of these 
protein pathways, which include inflammatory mediators, may contribute to the therapeutic 
resistance characteristic of MBC or the promotion of aberrant differentiation programs. We also 
pinpointed previously unconsidered differences in claudin, basal and luminal marker expression 
in MBC and TNBC, highlighting the relevance of individual patient stratification when 
considering heterogeneous malignancies. Further, we found concordant upregulation of the CCN6 
pathway proteins HMGA2 and IGF2BP2 in spindle MBC[108], which underscores the role of this 
pathway in the biology of this MBC subtype, and the advantage of personalized proteomics. 
In summary, this patient cohort identifies a common proteomic landscape of MBC in 
relation to TNBC, and highlights the existence of specific protein profiles underlying the different 
histopathological subtypes of human MBC. We show that quantitative proteomics refines the 
mutational landscape of MBCs and allows for further distinction of the tumor subtypes. We 
provide evidence for a significant overlap between MMTV-Cre;Ccn6fl/fl spindle MBC mouse 
model and human disease, which together with a common histopathology and transcriptome, 
validate this mouse model to test new treatments and mechanistic investigations on the 
development of spindle MBC. The subtype-specific proteomes of MBC tumors emphasize a 
unique opportunity to impact precision therapies to improve the survival of women with this 
aggressive form of breast cancer.  
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2-6  Figures  
 
Figure 2-1. Human clinical samples and quantitative proteomics workflow.  
a. Representative images of hematoxylin and eosin stained tissues from our patient cohort, 
including 15 metaplastic carcinomas (MBC, 6 spindle, 4 squamous, and 4 sarcomatoid), 6 triple-
negative (TNBC), and 6 normal breast. Scale bar = 50 μm.  
b. Workflow of quantitative mass spectrometry profiling. For data acquisition we assembled the 
27 samples into 3 experimental groups for 10-plex LC-MS/MS tandem mass tag (TMT) isobaric 
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labeling. For data processing and quantification, we used two novel pipelines, Philosopher/TMT-
Integrator, and generated a combined protein expression matrix for the 3 experiments used for 
downstream analyses, including hierarchical clustering, differential expression tests, statistical 








Figure 2-2. Pre-processing of LC-MS/MS TMT 10-plex proteomics data before and after 
data imputation and batch correction. a. Missing data percentages and patterns in each of the 
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three experiments 1, 2, and 3 (Exp = experiment) contained 18%, 14%, and 12% missing values, 
respectively. Scatter plots (middle) show one variable against all others (i.e. 26 comparisons 
between patients) and right plots are densities of imputed data against experimental data. The 
‘mice’ package was used in R (v3.4.0) with the parameters: m=5 (number of imputed data sets), 
method=pmm (predictive mean matching), and maxit=50 (number of iterations). The 
multivariate imputation by chained equations method is a gold standard data imputation 
algorithm that accounts for uncertainty in the data when values are missing at random following 
Rubin’s Rules (Rubin 1976 and 1987).  
b. Comparison of the raw data distribution of 27 patient samples with and without data 
imputation. Density distribution plots (top and middle) showing log2-transformed protein 
abundances for all TMT channels of 3 experiments, and an MDS scatter plot (bottom) of 
computed distances between protein expression profiles of all samples.  The asterisk (*) indicates 
the peak of missing values without data imputation. The table shows statistical performance 
(pooled estimates, p-values) of imputed data sets after fitting to a linear model and pooling the 
data to attain a median p-value<1.6E-03. The MS/MS spectra were first searched using 
MSFragger (v20181128) database search tool against UniProt human protein database 
(UP000005640), followed by processing by PeptideProphet with high-mass accuracy binning 
and semi-parametric mixture modeling to compute correct identification for each peptide-to-
spectrum (PSM) searching. PSM lists were created for each TMT 10-plex experiment, and 
protein groups were assembled in ProteinProphet filtered to 1% false discovery rate (FDR). 
PSMs passing through filters in the Philosopher label-free quantification module corresponded to 
TMT reporter ion intensities, and used as input to TMT-Integrator for normalization to the 






Figure 2-3. Quantitative proteomics of MBC, TNBC, and normal breast tissues.  
a. Principal component analysis (PCA) plot shows unsupervised clustering among the 27 
samples, demonstrating a clear distinction between normal and all tumors (MBC subtypes and 
TNBC) and between MBC squamous and sarcomatoid, while there was an overlap between 
MBC subtypes and TNBC. 
b. Heat map of the 5,670 proteins that passed through quality filters in TMT-Integrator across all 
patients. Significantly enriched downregulated (green) and upregulated (red) GO biological 
processes (p<0.05). Dendogram from hierarchical clustering analysis in Cluster 3.0 using median 






Figure 2-4. Summary of unsupervised k-means methods for determining optimal clusters. 
Table shows summary of results from seven different algorithms used in R (Bayesian, within-
cluster sum of squares (WSS), Vegan, Elbow, Gap statistic, Silhouette, and Apcluster) for 
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determining the optimal number of clusters among our cohort of patient tumor samples. 
Representative plots (top right) show hierarchical clustering heatmaps and a range of 2-4 optimal 
clusters found. Representative silhouette plot with 4 clusters shows an average silhouette width 
of 0.08, where silhouette ranges from -1 to 1. PCA plots (left) and table of corresponding 
histological subtypes (bottom right) demonstrate a distinction between normal and tumor (MBC 
and TNBC) with 2-3 clusters present, and a distinction between both normal and MBC subtypes 
(spindle, squamous, sarcomatoid) with 4-5 clusters, where triple-negative (TNBC) clustered with 







Figure 2-5. Supervised differential expression analysis reveals unique MBC protein 
signatures by histological subtype relative to normal breast. a. Total differentially expressed 
proteins in MBC and TNBC relative to normal tissues. Patient samples were grouped according 
 51 
to their predominant histological MBC subtype (spindle, squamous, and sarcomatoid), and 
considered proteins of p<0.05 and FC>1, and highly significant outliers of p<0.001.  
b. Statistical analysis shows volcano plots for MBC spindle, squamous and sarcomatoid and 
triple-negative (TNBC) subtypes as log2-Fold change versus –log10(p-value), where proteins 
indicated in green are downregulated and red indicates upregulated proteins. Horizontal 
boundary represents p=0.05 and two vertical boundaries indicate FC = 1 and -1. The list of the 
top 10 most significant up- and downregulated proteins are shown.  
c. Enrichment analyses of all MBC relative to normal breast tissues demonstrating up- and 
downregulated enriched terms from gene ontology (GO) using PANTHER (v14.1) database. 




Figure 2-6. Differential expression analysis shows deregulated proteins and pathways 
within histological subtypes of MBC and in relationship to TNBC.  
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Left, Volcano plots comparing MBC with TNBC and within MBC subtypes, as indicated. 
Significantly differentially expressed proteins are highlighted in red. log2-Fold change versus –
log10(p-value), where cutoff values on plots show FC > 1 or. FC < -1 (vertical lines) and p < 
0.01 (horizontal line), n = 20 patients. 
Right, Enrichment analysis using gene ontology (GO) annotations showing the top GO terms 
based on biological process, molecular function, or cellular compartment. Significant proteins 
were considered using p-value<0.05, q-value<0.1, fold change (log2-FC) greater than 1, 
Benjamini-Hochberg correction ("BH"), gene set size 5-500, and the total protein list (5670 
proteins) as the background set. Barplot shows significant terms by the gradient legend as 








Figure 2-7. Gene set enrichment analysis (GSEA) reveals distinct hallmark pathways 
within MBC subtypes and relative to TNBC.  
GSEA analysis show differentially expressed protein pathways in MBC compared to TNBC, and 
within MBC subtypes. Left, normalized enrichment scores (NES) versus the total list of GSEA 
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hallmark categories of up- and downregulated (marked “UP” and “DOWN”, respectively) 
significantly enriched terms (p-adjust <0.05) among non-enriched (p-adjust > 0.05). Right, top 
hallmark pathways highlighting unique significantly expressed categories. The GSEA analysis 
was performed using the clusterProfiler and fgsea package in R for the hallmark collection (“H”) 







Figure 2-8.  Top pathways of gene set enrichment analysis (GSEA) in Hallmark and KEGG 
gene sets within MBC and relative to TNBC. Ranked lists of gene sets were previously 
attained from differential expression analysis for each disease condition (MBC vs. TNBC, and 
across MBC subgroups (Spindle vs Squamous, Spindle vs Sarcomatoid, and Squamous vs. 
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Sarcomatoid) to run the GSEA analysis using MSigDB against hallmark gene sets and KEGG 
(Kyoto Encyclopedia of Genes and Genomes). Tables show top pathways, gene ranks, 
















Figure 2-9.  GSEA analysis of curated GO gene sets (“C5”) from MSigDB for MBC relative 
to TNBC, spindle vs squamous, and squamous vs. sarcomatoid. Bar plot shows the total 
number of differentially expressed up- and downregulated proteins in each category. Networks 
display most significant enriched terms from the GSEA: GO analysis including biological 
process, molecular function, or cellular component for each carcinoma condition. Node size 
depicts protein count (i.e. “gene count”), and all terms are significant and filtered to 
padjust<0.05. No significant terms were found between spindle and sarcomatoid MBC. 
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Figure 2-10. Top enriched pathway profiles distinguish among MBC subtypes and TNBC. 
GSEA enrichment plots of the highest up- or downregulated pathways by carcinoma type, 
including epithelial-mesenchymal transition (EMT), oxidative phosphorylation, interferon-γ, 
apical junction, TP53, MTORC1, and PI3K signaling, and MYC and E2F target pathways. The 
GSEA analysis was performed using the fgsea package in R for the hallmark collection (“H”) 






Figure 2-11.  Enriched protein networks of the top GSEA hallmarks and GO terms within 
MBC and relative to TNBC. Networks display most significant enriched terms and associated 
proteins for each carcinoma condition. Node size depicts protein count, and the color scheme are 
fold change values (log2FC), where red=upregulated and green=downregulated proteins. All 
terms were filtered at pval<0.05 and padj<0.05. 
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Figure 2-12.  Differential expression analysis between TNBC and all MBC subtypes. 
Volcano plots for spindle MBC vs. TNBC, squamous MBC vs. TNBC, and sarcomatoid MBC vs 
TNBC, as log2-Fold change versus –log10(p-value) and GSEA hallmark analysis (MSigDB 
v7.0), where top pathways are shown as p-adj <0.05 (blue). We followed the clusterProfiler 
package in R with n=1000 permutations and FDR <0.05. 
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Figure 2-13. Patient-stratified unsupervised differential expression analysis provides 
personalized signatures across MBC and TNBC tumors. a. Visualization of patient protein 
profiles of hallmark cancer phenotypes/phenomena including endothelial-mesenchymal 
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transition (EndMT), stromal cells, and epithelial-mesenchymal transition (EMT) / cancer stem 
cell (CSC) markers. Heatmap shows fold change values of each patient relative to the average of 
normal breast tissues.  
b. Stratification of patient profiles by well-known mammary gland proteins indicated by 
expression of claudin (CLDN3 and CLDN4), basal (KRT5, KRT14, KRT17) and luminal 
(KRT8, KRT18) markers.  
c. Patient stratification of two recently identified and novel MBC markers, IGF2BP2 and 
HMGA2, specific to spindle/squamous in mice compared with human proteome confirms their 
upregulated feature and reveals a significant outcome in MBC spindle and spindle/squamous 
compared with a downregulation in MBC squamous. One-way ANOVA statistical analyses were 
performed between subtypes, where p<0.05 was considered significant (*), and p<0.001 was 








Figure 2-14. Whole exome sequencing (WES) analysis shows repertoire of somatic 
mutations of MBC and TNBC.  
a. The landscape of somatic mutations common to MBC and within subtype-specific MBC 
histopathologies of 10 patients with MBC and matching normal breast tissues including spindle 
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(N=5), squamous (N=3) and sarcomatoid (N=2). The type of mutation is color-coded as 
indicated in the legend. Pathogenic mutational variants in MBC were defined as those of high 
complexity (1,011 of 11,652 total) were filtered in this analysis. Syn: synonymous, INDEL: 
inframe insertions and deletions. 
b. Heat map shows the top mutated genes with 20% of greater frequency of missense (blue) or 
loss-of-function mutations, “LoF” (dark blue). 
c. Venn diagram highlights the number common and distinct mutated genes in MBC subtypes. 
Bars show the frequency of the five commonly mutated genes (TP53, MUC17, PLEC, CRYBG2, 
ZNF681) in each subtype. 
d. Scatterplot is average allele frequency (AF) for each tumor sample, and colors represent 
metaplastic subtype. Enrichment analysis was performed using gene lists extracted for each 
MBC according to the gene-level variant and effect summary tables (GeneRollupv0.3.2).  
e. Top enriched GO and pathways (KEGG, Panther, or Reactome) of mutated genes in MBC 
subtypes. For this analysis, we excluded the variants with population allele frequency greater 
than 5% based on 1000 Genome Project data, and variants that fall in low complexity genomic 




Figure 2-15. Quantitative proteomics analysis of MMTV-cre;Ccn6fl/fl spindle MBC tumors 
identify a common signature with human spindle MBCs. a. Heat map of the 4,609 proteins 
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that passed through quality filters in TMT-Integrator for all samples (3 MMTV-cre;Ccn6fl/fl 
mouse tumors (KO) and 3 normal mouse mammary glands).  
b. Volcano plot comparing Ccn6fl/fl  tumors with normal mammary gland. Significantly 
differentially expressed proteins are highlighted in red. p<0.05 and absolute value FC > 1 were 
considered significant.  
c. Gene set enrichment analysis (GSEA) showing significant differentially expressed protein 
pathways in Ccn6fl/fl spindle MBCs compared with normal mammary glands. Normalized 
enrichment scores (NES) versus the total list of GSEA hallmark categories of up and down 
regulated hallmark pathways. 
d. Top hallmark pathways highlighting significantly expressed up and downregulated protein 
pathways (marked “UP” and “DOWN”, respectively). We used the molecular Signatures 
Database (MSigDB v7.0), hallmark gene sets with clusterProfiler and fgsea packages in R, with 
the biomaRT package in R to convert mouse gene IDs to human homolog associated gene 
symbols.  
e. Venn diagrams demonstrate the overlap between the proteome of mouse MBC and human 
spindle MBC tumors, relative to their normal tissue counterparts, identifying a 17-protein 
upregulated and 19-protein downregulated protein set. Protein-protein interaction networks of 
up- and downregulated signatures highlight potential markers of interest, along with functional 
enrichment analysis using STRING v11.0. Color scheme of network proteins are matched by the 
legend of GO enrichment terms in barplots. 
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Figure 2-16. Pre-processing of LC-MS/MS TMT 10-plex proteomics of MBC mouse model 
(MMTV-cre;Ccn6 KO). a. Representative histology images stained with hematoxylin and eosin 
(H&E) of normal mouse breast tissues and MMTV-cre;Ccn6 mouse tumors. Scale bar = 50 μm. 
Raw data distribution of 6 mouse samples, 3 normal breast tissues and 3 CCN6 knockout tumors. 
b. TMT channel vs log2(intensity) for all samples and density distribution plot of log2-intensity 
vs. density of all expression values per sample. 
c. Top hallmark pathways from GSEA analysis using MSigDB. Table shows gene ranks, 







Table 1. Clinical and histopathological features of the tumors in our patient cohort.  
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Chapter 3 ‒ A Reproducible Scaffold-free 3D Organoid Model to Study Neoplastic 
Progression in Breast Cancer 
 
The contents of the following chapter have been published in the Journal of Cell Communication 
and Signaling (2019) 13:129-143 (doi.org/10.1007/s12079-018-0498-7). Sabra I. Djomehri, Boris 
Burman, Maria E. Gonzalez, Shuichi Takayama, Celina G. Kleer 
 
3-1  Abstract   
While 3D cellular models are useful, gel-embedded organoids have large variability and 
slow transport of molecules to the matrix-encapsulated cells. This paper describes high-yield 
production of large (~1 mm diameter), scaffold-free, highly-spherical organoids in a one drop-one 
organoid format using MCF10A cells, a non-tumorigenic breast cell line. These organoids display 
a hollow lumen and secondary acini, and express mammary gland-specific and progenitor markers, 
resembling normal human breast tissue. Upon exposure to neoplastic conditions using TGF-β, a 
hypoxia-mimetic reagent, or co-culture with mesenchymal stem/stromal cells, the organoids 
increase collagen I production and undergo large phenotypic and morphological changes. 
Advantages of this scaffold-free, 3D breast organoid model include high consistency, ability to 
measure cellular collagen I production without noise from exogenous collagen, and capacity to 
subject the organoid to different stimuli from the microenvironment with precise timing without 
concern of matrix binding or slow diffusion. The morphological changes that accompany exposure 
to neoplastic conditions enable quantitative morphological analyses of the neoplastic progression. 
The method also allows for growth of organoids from cancer cells and primary tumors. The 
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platform is envisioned to be useful as a standardized 3D cellular model to study biomolecules from 
different neoplastic milieu as well as test potential therapeutics.    
 
3-2  Introduction   
The use of three-dimensional (3D) cell culture models has increased the understanding of 
breast cancer progression, enabled testing of new treatments, and may offer a unique platform for 
high throughput analyses of molecular changes during breast initiation, progression, and 
metastasis. However, novel models that better recapitulate the mammary gland architecture while 
also offering reproducible quantitative parameters are needed.  
Being more physiologically relevant than conventional two-dimensional (2D) culture, cells 
grown in 3D are capable of organizing into distinct phenotypes resembling miniature functional 
units of the breast. Early investigations using a laminin-rich matrix, commonly known as Matrigel 
[11],[13], or a collagen matrix [128], as a reconstituted basement membrane demonstrated that 
mammary morphogenesis, mammary gland branching, and discernment of normal and neoplastic 
mammary phenotypes are assayable domains. Notable follow-up studies laid the framework for 
standard 3D culture procedures for breast models existing today [10],[65]. In this system, non-
tumorigenic MCF10A cells form 3D microstructures called acini, which are generated either by 
embedding cells inside or on top of Matrigel. These scaffold-based systems have particular 
advantages when studying early events of tumor initiation, cell-ECM biophysical interactions 
[66],[74] and tumor migration and invasion [76],[129],[64]. However, although these systems 
recapitulate facets of the in vivo microenvironment with Matrigel substituting as a rudimentary 
extracellular matrix (ECM), the ECM scaffold can adsorb and trap growth factors, cytokines, and 
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chemokines as well as slow diffusion of therapeutic molecules to the cells complicating studies of 
the effect of different factors administered at different times. 
Liquid-based systems, on the other hand, like the hanging drop technique, allow for media 
exchanges and administration of chemical components with flexible timing. Others have achieved 
spheroid reproducibility using 96-well hanging drop systems [76],[77] and even automated 
hanging drop culture with digital microfluidics [80] to generate a single spheroid per well. We 
have also developed a high-throughput 384-well hanging drop platform [81] that simplified the 
conventional hanging drop method, including optimized media additives [82]. The 
macromolecular additive methylcellulose (MethoCel) and a low concentration of Matrigel to the 
culture media only upon cell seeding contributed to highly uniform, compact spheroid 
morphologies. This system has allowed the development of spheroids from breast cancer cells 
[82], but until now has not been well explored using non-tumorigenic mammary epithelial cells to 
achieve consistent 3D structures, which demonstrate the challenges of slow or inefficient 
reaggregation capacity in a liquid-based setting [130]. 
Recent advances in cell culture are steering research towards organotypic culture (Fig 3-
1A). Organotypic culture is characterized by the physiologic interaction of multiple cellular 
phenotypes to recapitulate the fundamental unit of the tissue of origin, the resulting cellular 
constructs often referred to as “organoids,” whereas “spheroids” loosely describe 3D structures or 
cellular aggregates that may self-organize but need not recapitulate a tissue-like behavior (diagram, 
Fig 3-1B). Here, we define an “organoid,” similar to that described in a recent review [68], as a 
3D structure that self-organizes in culture to reproduce the basic functional unit of the native tissue. 
In this study we use a scaffold-free 384-well hanging drop system to culture non-
tumorigenic mammary MCF10A cells and show that they are able to expand into organoids that 
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resemble the architecture of normal human breast including presence of multiple cellular 
phenotypes [10]. We demonstrate 1) that laminin-rich components and not a laminin-rich matrix, 
together with a simple crowding agent and FBS in 3D suspension culture is sufficient to support 
formation of mammary acinar structures of high reproducibility, and 2) the formation of a large, 
self-organized mammary gland (MG)-like organoid structure using scaffold-free culture capable 
of exhibiting multiple lineage phenotypes. Importantly, we provide a new physiologically relevant 
3D organoid model, able to recapitulate normal breast and neoplastic breast cancer progression.  
 
3-3  Methods   
Cell lines and cell culture. MCF10A and MDA-MBA-231 cell lines were obtained from the 
American Type Culture Collection (Manassas, VA). MCF10A, an immortalized non-transformed 
human breast epithelial cell line, is a well-established in vitro model of the benign breast. MCF10A 
are near-diploid cells with stable karyotype. MCF10A cells were cultured in growth medium 
containing DMEM/F12 (Invitrogen #11965-118), Horse serum (Invitrogen #16050-122) and 
supplements as previously reported by Debnath and colleagues [10] and MDA-MB-231 cells were 
maintained as per the manufacturer’s instructions with culture medium composed of DMEM 
(Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS). DsRed-labeled mesenchymal 
stem cells (MSCs) were generated by the Kleer Lab, where MSCs were isolated from fresh human 
breast cancer metastasis tissue (The Tissue Procurement Service at the University of Michigan, 
IRB#HUM00050330). MSCs were maintained as reported by Gonzalez et al. [131]. All cells were 
cultured at 37 C and 5% CO2 in 100 mm culture dishes, supplemented with 1% antibiotic-
antimycotic, passaged before ~75% confluence was reached, and monitored with brightfield 
images collected at 10x magnification.  
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3D culture  
A hanging drop array system was used to generate high-throughput 3D organoid culture in 
a 384-well format [81]. Hanging drop plates were coated in 0.1% Pluronic F108 (BASF) and UV 
sterilized. Hanging drops were formed using cell suspension solution with optimized media 
additives [82], 0.24% (w/v) methylcellulose (A4M MethoCel, Dow Chemical, MI) and 1.5-2% 
(v/v) Matrigel (growth factor reduced, phenol red-free, BD Biosciences, #356231), where 25 μl 
droplets were maintained. MCF10A cells were seeded at a density of 3,000 cells per droplet, MDA-
MB-231 cells were seeded at 2,000 cells per droplet, and co-cultures with MCF10A and MSC cells 
were seeded at 1:1 with 2,000 total cells per droplet. To avoid evaporation, the array plate was 
sandwiched between a 96-well plate (Corning Costar 3596, Corning Inc., Lowell, MA) and plate 
lid to create a humidified environment. Fresh media was replenished every 2-3 days using a liquid 
handler (CyBi-Well, CyBio, Inc., Jena, Germany). Approximately 8-9 μl solution was removed 
from a drop and 9-10 μl fresh media added into a drop, repeated twice. For MCF10A organoids, 
we also added 10% FBS to the seeding solution to enhance organoid growth, and after spheres 
formed at day 3, we removed Matrigel, FBS, and MethoCel from the droplets with ~3 washes and 
replaced with complete media [10],[82] for the duration of culture. All organoids were maintained 
for 16 days and monitored by phase-contrast imaging (Nikon Eclipse TE300 inverted microscope). 
For comparison, MCF10A cells were seeded and maintained in a 96-well 3D format using the 
exact same parameters as in 3D hanging drop cultures except using 100 μl volumes and for media 
changes, 32 μl was removed from wells and replaced with 34 μl fresh media during each wash.  
3D epithelial-to-mesenchymal (EMT) induction assays 
Epithelial-to-mesenchymal induction assays were performed in the hanging drop system 
using MCF10A cells treated exogenously with either human recombinant TGF-β1 (Sigma, GF346) 
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or a hypoxia mimetic, CoCl2 (Cobalt(II) Chloride 97%, Sigma, 232696). TGF-β1 and CoCl2 
solutions were prepared following manufacturer’s instructions. For TGF-β1 induction assays, 
MCF10A organoids were grown for 5 days in hanging drop plates, followed by serum starvation 
of the droplets for 16 hours using serum-free DMEM/F12 medium (Invitrogen #11330-032). TGF-
β1 was added to the serum-free medium, and a final concentration of 10 ng/ml TGF-β1 was added 
to droplets upon media exchanges and replenished after 2 days. Organoids were exposed to TGF-
β1 for 4 days and removed from droplets with 7-8 washes of complete medium. For another 6 
days, organoids were grown with complete medium and harvested from the plates. For CoCl2 
assays, hypoxia induction was performed as previously reported [132]. MCF10A organoids were 
grown as usual for 5-6 days. CoCl2 was added directly to regular complete medium to induce a 
hypoxia-like response at a final concentration of 100 μM CoCl2 for 24 hours. CoCl2 was removed 
with 7-8 washes of complete medium, and organoids were allowed to grow for another week before 
harvesting. 
Cryoblock embedding and sectioning 
Organoid samples were collected from the array plate at a desired time, rinsed once with 
1x PBS (GIBCO #10082), fixed in 4% PFA solution for 2 hours at room temperature, and washed 
again three times in 1x PBS. Prior to embedding, fixed organoids were stained with 0.1% (v/v) 
methylene blue for 10 min and rinsed with PBS. Next, a thin layer of optimal cutting temperature 
(OCT) compound (Tissue-Tek, Sakura Finetek, CA, #4583) was placed into a 5x5 mm cryomold, 
and the desired number of organoids were pipetted into the OCT layer. Additional OCT was filled 
to the top of the cryomold and snap-frozen on dry-ice, in block form, for 10 minutes in a Styrofoam 
container. The frozen blocks were stored at -80 C, and subsequently sectioned into 5 μm sections 
on a Lecia 3050S Cryostat (Leica Biosystems Inc., IL) and mounted onto slides for staining. 
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H&E and Immunohistochemistry (IHC) 
After thawing for 5 minutes, slides with sectioned organoids were rehydrated with 1X TBS 
buffer for 10 minutes. Heat induced epitope retrieval was performed with FLEX TRS Low pH 
Retrieval buffer (6.1, Dako, Carpinteria, CA) for 20 minutes. After peroxidase blocking, the 
antibody Collagen 1 rabbit polyclonal (Abcam, #ab34710) was applied at a dilution of 1:500 at 
room temperature for 60 minutes. The EnVision + Rabbit HRP System was used for detection. 
DAB chromagen was then applied for 10 minutes. Slides were counterstained with Harris’ 
Hematoxylin and Eosin (H&E) for 5 seconds and then dehydrated and coverslipped. For mouse-
derived organoids, primary antibodies used included Ki67 and Cleaved Caspase 3. Ki-67 rabbit 
monoclonal (Cell Marque, SP6 #475 R-16, Rocklin, CA) was applied at a dilution of 1:250 at room 
temperature (R.T.) for 30 minutes, and Cleaved Caspase-3 rabbit polyclonal (Cell Signaling 
#9661, Danvers, MA) at a dilution of 1:300 at R.T. for 60 minutes. To compare with organoid 
sections, we prepared H&E sections on human breast tissues samples obtained from University of 
Michigan (IRB approval HUM00050330). 
Immunofluorescence and confocal imaging 
Sectioned organoids were immediately fixed in 70% (v/v) methanol and stored at -20°C. 
After fixation, blocking of nonspecific binding of the antibodies was accomplished by incubation 
with Background Sniper (BioCare Medical, Pacheco, CA) for 30 min, followed by incubation 
overnight at 4°C with pairs of primary antibodies (mouse and rabbit). Primary antibodies included 
anti-E-cadherin (1:100, mouse monoclonal antibody, clone HECD-1, Thermo Fisher Scientific, 
Waltham MA, 13-1700), anti-CK5/6 (1:100, Thermo Fisher Scientific, Mouse monoclonal 
antibody, clone D5/16 B4), anti-CK18 (1:100, Rabbit monoclonal antibody clone ER431-1, 
AbCam, Cambridge, Ma, Ab32118), and anti-Vimentin (1:300, Rabbit monoclonal antibody, 
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clone EPR868(2), AbCam, Ab133260). After washing with Tris buffered saline (10 mM Tris HCl, 
pH7.4/ 0.154 M NaCl) containing 0.1% Tween 20 (TBST), the slides were incubated with 
fluorescent-conjugated secondary antibodies Cy3 and Cy5 for 30 minutes (1:200, #A10520-21, 
#A10523-24, Thermo Fisher Scientific) diluted in background sniper. After additional washes with 
TBST, sections were mounted using Prolong Gold (Thermo Fisher Scientific) containing 4′,6-
diamidino-2-phenylindole (DAPI) and confocal images were captured with a Nikon A-1 Spectral 
Confocal microscope using a 20X and 40X oil objective. 
Western Blot 
Cells were collected and subsequently lysed in RIPA lysis buffer with protease and 
phosphatase inhibitors (Thermo Scientific #78410) at 100x dilution. Western blots were performed 
using 40µg of total protein, separating the protein samples by SDS-PAGE gel and transferring onto 
PVDF membranes. The membranes were blocked in TBS-T (Tris-buffered saline, 0.1% Tween 
20) and 5% milk, and then incubated with primary antibodies in TBS-T at 4°C overnight. Abcam 
antibodies: CD49f (#AB112181), Vimentin (#AB16700), CD44 (#AB51037). Cell Signaling 
antibody: E-cadherin (#3195). Thermo Fisher antibodies: ALDH1A1 (#PA5-11537), EpCam 
(#710524). B-Actin-HRP (Santa Cruz, #47778) was used as a loading control.  
Mouse-derived organoids (CCN6 knockout (KO) tumors) 
CCN6 KO tumors from genetically engineered mice developed in the Kleer lab [62] were 
dissociated into tissue fragments and single cells prior to organoid generation. Tumor samples 
were washed for 5 minutes in 1x PBS, pH 7.4, then manually cut into small fragments (>1mm 
diameter) with a scalpel, tissue fragments were mechanically and enzymatically dissociated into a 
single-cell suspension using the MACS Tumor Dissociation Kit- mouse (Cat# 130-096-730, 
Miltenyi Biotec). After centrifugation and media aspiration, the remaining tumor cells together 
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with the cancer-associated stroma were resuspended in suspension media containing DMEM, 1x 
B27, 1x insulin transferrin selenite ethanolamine, 1x non-essential amino acids, EGF (10ng/ml), 
bFGF (10ng/ml), and 1x antibiotics. The cell suspension was then used to perform 3D hanging-
drop culture as previously described. After 20 days, mouse-derived organoids were harvested, 
embedded, and sectioned as described above. 
Morphological metrics and phenotypic assessment 
Image processing for all morphological parameters was done in ImageJ software using the 
Watershed algorithm and binarization techniques as previously discussed [133]. The 
morphological parameters average organoid diameter, sphericity, and hollowness were measured 
by standard image segmentation techniques in ImageJ software using adaptive thresholding with 
the Watershed algorithm and binarization to create a mask of organoid boundaries. Morphological 
features were measured in triplicate with N=10 organoids for each group of cells and conditions, 
as indicated. Best fit ellipsoids of irregular organoid shapes were determined for average diameter 
and sphericity measurements using Feret’s statistical diameter as an approximated equivalent 
diameter. Sphericity (named "circularity" in ImageJ) was measured as a ratio between 0 to 1, 1 
being a perfect circle. The % hollowness was determined as a ratio of total area of cell and matrix 
regions to total organoid bounding area. For phenotype quantification, we measured the percentage 
of positive cells per organoid section by manual counting. This was calculated using threshold 
adjusted immunofluorescence signals from a Nikon E-800 microscope, with N=75-150 cells per 
organoid section and N=5 organoids per subgroup, and the results were triplicated. Similarly, we 





Results were expressed as means ± standard deviations and statistical analysis was 
performed using one-way ANOVA tests for morphologic and phenotypic data at days 8 and 16. 
Statistical significances of P<0.05 and highly significant P<0.001 results were considered. At each 
time point, ANOVA tests were carried out between non-tumorigenic (MCF10A), tumorigenic 
(MDA-MB-231) and neoplastic (co-culture, CoCl2, TGFβ1) organoid subgroups.  
 
3-4  Results & Discussion   
Establishment and expansion of a scaffold-free 3D MCF10A breast organoid model 
 Modeling neoplastic progression in mammary organoids with multiple phenotypes and  
mixed cell populations remains a challenge [134]. A classic work by Wellings and colleagues [7] 
further supported by recent studies investigating cell-of-origin of breast cancers, suggests that 
human breast cancers originate from cells within the terminal duct lobular unit (TDLU, Fig. 3-
1A), a composite of a duct and several lobules. In this study, we have generated a 3D mammary 
gland-like structure that resembles some of the signature and structural aspects of the normal 
breast. 
In a previous report from our group [82], we found improved spheroid formation in a 384-
well hanging drop system on spheroids derived from cancer cell lines using both Matrigel, collagen 
and other ECM hydrogel scaffolds. However, MCF10A cells could not be made to aggregate into 
tight single structures under these conditions (Fig. 3-2A no FBS conditions). Here we show 
conditions to form tight aggregates and further show that this scaffold-free environment allow 3D 
MCF10A organoids with hollow lumens to expand up to diameters of 1.2 mm as well as display 
multiple lineage markers (Fig. 3-1A, top panel). The large 3D organoids may also contain one or 
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more acini (Fig. 3-1A, bottom panel, acini indicated by white arrows). Because these features are 
distinct from previous reports of MCF10A acini [10],[64],[129],[14], and produce multiple cell 
lineages as should be observed in organotypic cultures [135], we refer to these 3D structures as 
MCF10A organoids.  
Typically, MCF10A acini in the literature including studies from our lab [65],[64],[129], 
have matched physiologic acinar sizes (50-200 μm), but the MCF10A organoids formed here in 
hanging drop ranged from 900-1200 μm and 1070 ± 105 μm average diameter after 2 weeks in 
culture and typically exhibited multi-acinar structures resembling aspects of normal breast TDLU. 
These differences are depicted in Fig. 3-1B, which shows conventional MCF10A scaffold-based 
culture with polarized acini embedded in Matrigel (leftmost) or conventional spheroids grown in 
U-bottom plates (middle), MCF10A organoids developed in this study (rightmost), and legend 
showing typical sizes of the different biological structures formed in 3D. The size of the organoids 
may reflect not only the tightness of cellular interactions within the organoid but may also be a 
critical determinant of cell biology [136]. As seen in recent organotypic culture studies, larger 
sphere sizes may correlate with the ability of organoids to generate and display multiple 
phenotypes in 3D, as with multilayered optic cup structures from hESCs of ~550 μm diameters 
[130], to human brain organoids of ~2 mm diameters that produced regions of multiple cell types 
[137]. 
More critically, the use of MCF10A as a suitable cell line to model normal breast cell 
function has been established in the field [10],[13],[71]. More recently, Qu and others [75] found 
a mixed luminal and basal expression was observed. Our results confirm mixed luminal and basal 
expression of MCF10A organoids. As shown in Figure 3-1, MCF10A organoids expressed the 
basal marker cytokeratin (CK) 5/6 on the basolateral side, and luminal markers CK 18 and E-
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cadherin on the apical side facing the lumen. Cytokeratin status has been intensely studied in 
clinical pathology on breast lesions and benign tissue, with distinct phenotypes described as 
stem/progenitor (CK 5/6+), glandular progenitor (CK 5/6+ and CK 18+), and committed glandular 
(CK 18+) [9],[138]. Interestingly, a population of CK 5/6+ cells on the basolateral side of 
MCF10A organoids appeared to co-express CK 18, suggesting glandular progenitor status. 
Supporting these data, recent studies generating TDLU-like organoids from primary human 
mammary epithelial cells found that the TDLU signature consisted of a co-expression of multiple 
lineage makers at similar positions as we observed in MCF10A organoids and in normal human 
TLDU [134],[15]. Together, these results support that the MCF10A model, when grown into 3D 
organoids, recapitulates some of the cellular heterogeneity of the normal breast TDLU.  
Growth and remodeling of normal mammary organoids  
The ability to form physiologic acinar structures in 3D is generally thought to require a 
scaffold-based setting because the support matrix provides the necessary pseudo-basement 
membrane. However, based on our studies, we postulate that the scaffold material itself might limit 
organoid expansion, by mechanical constraints and/or limiting the supply of critical nutrients 
[139], thus, MCF10A 3D structures only develop into smaller acinar structures of singular 
phenotype. 
Since non-tumorigenic MCF10A cells are known to form acini in 3D without stemness 
capacity [75], we predicted low expansion ability in hanging drop. However, we found that a 
combination of low Matrigel concentration (~1-2%) and higher serum (10% FBS) at seeding 
strikingly promoted expansion of organoids (Fig. 3-2A), which was similar to a recipe of additives 
noted in organotypic culture, where self-forming 3D retina from hESCs used 1% Matrigel and 
10% FBS over 18 days [130]. We also compared MCF10A cells grown in 96 well U-bottom plates 
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(H&E sections, Fig. 3-2A) and found greater hyperplastic regions within the lumens of the 
organoids in U-bottom plates compared to hanging drop organoids.  
To further optimize the system, we explored organoid formation at varying concentrations 
of media-dissolved Matrigel over 3 days (Fig. 3-2B, Fig. 3-3). In the absence of Matrigel, 
MCF10A forms highly compact spheres but were unable to differentiate beyond a cellular 
aggregate (Fig. 3-2C), 1% (v/v) Matrigel was the minimum concentration needed to observe 
differentiation, while increasing to 2% Matrigel rendered lower aggregate-forming ability. Thus, 
we achieved one large organoid per droplet at 95% forming efficiency using 1.5% Matrigel and 
10% FBS over 3 days, an optimal recipe to establish uniform spheres. This is consistent with 
literature, in which FBS was shown to augment and enhance cellular differentiation [130], while 
increasing Matrigel concentrations can decrease the number and function of acini formed [140]. 
We found by keeping cell seeding number and all other culture parameters constant, 
MCF10A organoid sizes increased by ~75% every 4 days for 16 days, co-culture and cancer 
organoids had slightly slower growth, while 10A MG‒ spheres and EMT transformed organoids 
stopped proliferating after days 4 and 8, respectively (Fig. 3-2C). This suggests our cocktail of 
additives is critical for generating reproducible, uniform spheroids that can expand long-term, as 
shown by their range of sizes across cell subgroups (Fig. 3-2C), which has been a major challenge 
with conventional 3D platforms. 
Available data suggest that hanging drop culture might provide advantages over other 3D 
spheroid assays for achieving organoid expansion. For example, conventional 3D gel embedded 
or on-top Matrigel culture of benign MCF10A acini [14], and 3D microfluidic and PDMS 
microwell systems for cancer spheroids [141],[78] show significant restriction in size (<300 μm 
diameter) and proliferation potential, possibly due to mechanical confinement. Also, a recent study 
 84 
using microsensors found oxygen levels of multi-spheroids grown in conventional U-bottom 96 
well plates dropped significantly after 18 hours, while hanging drops containing one spheroid had 
stabilized oxygen values [139]. Our observation of irregular morphologies, lumen filling, and no 
acini formation in 96 well U-bottom plates (Fig. 3-2A), suggests that hanging drops are organoid-
supportive by providing more oxygen, by enhancing autocrine effects relative to the 96 well plates 
by using smaller media volumes, or by other unknown mechanisms. 
 We next investigated whether the expansion observed in MCF10A organoids reflected a 
stem cell population since organoids described in literature are either propagated by stem cells 
(e.g. mammary progenitors, hESCs, iPSCs) or maintained by a known stem cell population. 
Western blot analysis of MCF10A organoids demonstrated the presence of a stem cell population 
with an EpCAM+/CD49f+/ALDH1+/CD44+ phenotype (Fig. 3-4). This is an important finding 
since previous studies of MCF10A cells in 3D Matrigel systems were not able to observe stem cell 
populations or reported a loss of stem/progenitor markers when moving from monolayer to 3D 
[75]. This suggests the MCF10A cell line, in the absence of ECM scaffold, could be maintained 
by a self-renewing stem/progenitor cell population in 3D culture allowing substantial expansion. 
This may be a potential advantage of growing cells in a free floatation context, whereby the 
investigation of stem cell populations over time can be readily monitored despite having less 
physiologically relevant ECM mimicry than typical 3D scaffold systems.  
Organoids as models of neoplastic progression 
We next compared the phenotypic features of normal MCF10A cells grown with and  
without Matrigel, and MDA-MB-231 breast cancer organoids in our model, noting similarities and 
differences with other 3D breast models [65],[142]‒[129]. By day 8, MCF10A organoids develop 
a hollow lumen similar to acini [10] but unlike typical acini embedded in an ECM gel, the 
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organoids are able to grow (approximately 700 μm in diameter), and form a complex network of 
acini, resembling a normal human TDLU in tissues (Fig. 3-5, in vivo TDLU image, leftmost 
column; arrows indicate acinar structures). This contrasts with the limited 3D growth of MCF10A 
formed under suboptimal conditions (MG‒) which remain as cellular aggregates and do not exhibit 
tissue-specific markers (Fig. 3-5, middle column), and with MDA-MB-231 breast cancer 
organoids that display an invasive phenotype similar to that of invasive breast carcinoma in clinical 
tissue samples (Fig. 3-5, rightmost panel) [129]. Over time, from day 4 through 16, MCF10A 
organoids undergo significant remodeling with lumen clearance, reduction of ECM matrix, and a 
tendency toward strict circular morphologies with increasingly cord-like basolateral peripheries 
(Fig. 3-6A). Together, these results demonstrate that the hanging drop organoid system allows 
expansion of the cell populations with normal and neoplastic phenotypes, which can be applied to 
the study of breast tumorigenesis.  
 To directly test whether the MCF10A organoid platform in hanging drop is useful to study 
changes that occur during neoplastic progression, we subjected our model to different treatments 
shown to induce an epithelial-to-mesenchymal transition (EMT), an important process during 
tumorigenesis [25]. MCF10A and other normal breast epithelial cells cultured in Matrigel were 
shown to undergo EMT and malignant transformation upon exogenous treatments 
[10],[142],[143], but whether these changes occur in scaffold-free 3D culture is unknown. We 
found that treatment of MCF10A organoids with TGFβ1 and the hypoxia mimetic agent, CoCl2, 
two well established inducers of EMT and neoplastic transformation, led to a widespread loss of 
E-cadherin and increase in vimentin expression, which are hallmark responses of EMT (Fig. 3-7) 
[144]. 
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We selected treatment with TGFβ and the hypoxia-mimetic agent given their reported 
effect in induction of EMT and malignant transformation in breast cancer. Tests using TGFβ-
induced transformation have been used more commonly in 2D MCF10A models [31]‒[145] than 
in 3D, with few reports utilizing a MCF10A gel-embedded system [70]. Studies of hypoxia and 
MCF10A acini have been even fewer, in which hypoxia chambers were used, but these were 
unsuccessful in detecting EMT in MCF10A 3D culture [146]. More recently, we found the 
literature points to certain chemical agents able to induce hypoxic effects rapidly, within minutes 
of administering, generating strong responses and higher controllability than hypoxia chambers 
[147]. Thus, we optimized a protocol using CoCl2 induction from Wu and Yotnda [132] and 
successfully generated rapid EMT-driven responses after just 24 hours (Fig. 3-8A, H&E sections). 
For both TGFβ1 and CoCl2 induction, we found significant deviation from normal MCF10A 
organoid morphology and signatures over days 8 through 16, with key differences highlighted in 
Figure 3-6B. 
The ability to produce collagen and other ECM components has been ascribed to stromal 
cells [148] and to cancer cells [149]‒[150]. Unexpectedly, we found that TGFβ and CoCl2- induced 
a strong fibrotic-like response (Fig. 3-8A, Fig. 3-6B, collagen I stains). Quantification of 
immunostaining results for TGFβ1 and CoCl2 treated MCF10A organoids showed increased 
collagen I compared to untreated controls and were similar to levels observed in stromal cells and 
cancer cells (Fig. 3-8A, bottom plot). These data reveal the previously unknown ability of 
MCF10A cells to undergo de novo synthesis and deposition of collagen I upon EMT induction. 
Since conventional 3D gels often make use of collagen-containing matrices, the production of 
collagen from transformed normal epithelial cells would be an indiscernible or challenging feature 
to capture. The results indicate that benign breast cells such as MCF10A may have an inherent 
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plasticity that is revealed by using a gel-free culture platform. We also show that the de novo 
remodeling processes can easily be detectable by H&E or IHC analyses. From a clinical 
perspective, the 3D organoid system can be applied to study ways to inhibit stromal fibrosis in 
cancer progression using pharmacological approaches. 
Organoids allow epithelial-stromal cross-talk  
The microenvironment consisting of stromal, immune, and vascular cells as well as 
structural ECM components has been shown to exert a powerful influence on breast cancer 
initiation and progression [2]. Physiologically relevant in vitro models to study these interactions 
are needed. Towards this end, we generated a 3D heterotypic model with a simple test 
compartment of MCF10A and MSCs (Fig. 3-8B; MCF10A=blue, MSC=red). 
Comparing to non-tumorigenic MCF10A organoids at day 8, co-culture organoids were 
significantly altered, with key features being disruption of CK5/6 expression, no acini formation, 
and lumen filling (Fig. 3-8B, H&E and confocal images). We also noted spindle-like MCF10A 
cell phenotypes and loss of cell-cell contact. These features reflect the profound influence of MSC-
epithelial cell interactions, and suggests that the increased collagen output by MSCs may induce 
EMT on MCF10A cells (Fig. 3-8A, Fig. 3-6B). This is consistent with studies from our lab, which 
showed that direct contact with MSCs induced a spindle morphology and increased migration and 
invasion of MCF10A cells through the collagen receptor DDR2 in co-culture experiments [131]. 
Our 3D organoid platform may be useful to study the details and consequences epithelial-stromal 
cross-talk during neoplastic initiation and progression and may offer an ideal system to test new 
therapies to block the stromal pro-tumorigenic influences on epithelial cells.  
To investigate whether our new model can be used to grow fresh tumors, we set out to 
generate organoids derived from Ccn6fl/fl;MMTV-Cre mice, a breast cancer mouse model of 
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metaplastic carcinomas developed in our lab [62]. These tumor-derived organoids contain cancer 
cells, and cells from the stromal and immune compartments. Methods for generating mouse 
mammary organoids in 3D culture have been limited, and typically describe propagation of 
epithelial organoids [151]. In addition, we demonstrate detectable protein expression (e.g. 
proliferation marker Ki67 and apoptotic marker cleaved caspase 3). Because of growing interest 
in patient tumor derived organoids for purposes of biobanking [152] and single cell sequencing 
[153], these efforts have mainly focused on the primary epithelial compartment, but there is a great 
need to expand our understanding of patient intratumoral heterogeneity analyses. Our results of 
mouse-derived organoids show a step in that direction, forming in a highly reproducible format 
over shorter time periods.  
Overall, the two major substrata used in 3D breast models, collagen I gels and Matrigel, 
are essential for providing the context whereby systemic cues can mimic the microenvironment, 
such as directing gene expression and cell responses [73]. But there are no specific guidelines for 
3D systems on how best to mimic particular features of the in vivo situation [136]. Although use 
of a scaffold can preserve MCF10A acinar mechanical integrity by reproducing pressure forces 
like those found in vivo [71], spheroids grown under free suspension may not experience similar 
pressure cues, which could be a potential drawback. The lack of ECM biophysical forces could 
explain why MCF10A organoids undergo substantial expansion to approximately twenty-five 
times the size of normal breast acini. Even though as a structural unit, they are larger than the 
reported in vivo range, their ability to expand highlights a tight cellular commitment to the normal 
morphogenetic program.  
Moreover, a major disadvantage of gel systems is their restricted ability to express tissue-
specific markers [154]. Our data support the idea that a 3D free-floatation context might provide 
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a more permissive environment for differentiation as previously stipulated [68]. Thus, a general 
guideline for investigators using scaffold or suspension systems is to consider the relevant 
biophysical and spatiotemporal factors to facilitate a desired outcome. 
Assessment of morphologic and phenotypic parameters of normal and neoplastic 
progression in organoids 
Despite an increase in studies using 3D tumor models in recent years, there remains a lack 
of standardization in spheroid and organoid analyses. Some investigators advised monitoring a 
combination of morphological parameters [79],[155],[156] such as volume, sphericity, and area, 
however this information can be quite variable in the literature, stemming from inconsistencies in 
reproducibility and uniformity. Therefore, it is important to use a quantifiable metric to link our 
“observables” to biological relevance. With this outlook, we performed morphometric analyses on 
organoid parameters for average diameter, sphericity, hollowness, and phenotypic analyses on 
epithelial-like (E-cadherin+), mesenchymal-like (spindle +), basal / progenitor (CK5/6+), and 
fibrotic-like (Col1+) features for all tested organoid subgroups, i.e. non-tumorigenic (MCF10A), 
tumorigenic (MDA-MB-231), and neoplastic (co-culture, CoCl2, TGFβ1) (Fig. 3-9).  
ANOVA tests performed across all culture conditions for organoid-level morphologic and 
cellular-level phenotypic parameters at days 8 and 16 were statistically highly significant 
(P<0.001) (Fig. 3-9A). We found from days 8 to 16, sphericity and hollowness had diverged across 
conditions resulting in decreased P-values (P<1E-06). Since tumorigenic and non-tumorigenic 
morphologic parameters become well distinguished at 16 days, this suggests sphericity and 
hollowness could be suitable biological indicators for analyzing dynamic changes in organoids in 
short-term culture. Others have also noted overall shape is a highly variable parameter yet crucial 
indicator of tumorigenicity, as in a recent study that examined over 100 primary breast cancer 
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organoid lines [157]. The improved significance over time suggests when looking for distinct 
morphologic traits in organoids, they should be cultured > 2 weeks.  
On the other hand, all cell phenotypic features were distinct by day 8 for all organoid 
subgroups (P<1E-08) (Fig. 3-9A). For neoplastic organoids, mesenchymal and fibrotic-like 
features converged to a tumorigenic phenotype just 2 days after treatment, with increased P-values 
at day 16 (P=0.005 and P=0.19, respectively), becoming phenotypically indistinguishable to 
MDA-MB-231 organoids. Thus, although organoid phenotypes are statistically unique, upon 
neoplastic progression they become harder to distinguish. As a result, we observed that epithelial 
and basal traits were harder to decipher since over time significances did not change as much as 
mesenchymal and fibrotic-like traits in response to a treatment. In relating phenotype to 
morphology, we found organoid sizes < 400 μm in general do not display organotypic expansion 
or differentiation (e.g. 10A MG‒ 3D structures), whereas after organoids reached > 800 μm in 
diameter, we detected unique multi-phenotypic and multi-morphologic states, summarized in the 
Figure 3-9B table. Here, sphericity/lumen status provided approximate regimes as follows: a 
normal epithelial, non-fibrotic state (> 0.75), a mesenchymal, fibrotic-like “invasive” state with 
largely filled lumen (< 0.5), and a mixed phenotype “irregular” regime (0.5-0.75) reflecting all 
neoplastic states (e.g. EMT, cancer, heterotypic). 
Highly-reproducible 3D evaluations can form a basis for future experiments involving 
patient-derived organoids, which can in turn facilitate the study of large-scale drug screening and 
patient organoid biobanking [158] to guide personal therapies. We advise a quantitative analytical 
assessment based on a combination of morphological and phenotypic parameters for 3D tumor 
models, outlined in the Figure 3-9B table, which can be applied across cell types and conditions. 
In relating morphology with phenotype, filled lumen status and fibrotic-like features of neoplastic 
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organoids could reflect an ability to produce their own ECM which normal epithelial cells clearly 
lacked. However, those more difficult to discern traits such as basal / progenitor status, which 
might drive organoid regeneration, suggest an underlying mechanistic complexity to be followed 
up in future studies. Our model offers important advantages over previous organoid and 3D 
embedded culture methods, which are summarized in Table 3. 
In summary, the present work describes a non-embedded, gel-free, hanging drop culture 
that enabled consistent production of highly-spherical MCF10A non-tumorigenic breast organoids 
with surprisingly large diameters in good yield. We further developed neoplastic breast organoids 
also with uniform, reproducible sizes and shapes, making it easy to standardize against other 
parameters. The obtained MCF10A organoids contain cells of multiple phenotypic lineages 
including tissue-specific and progenitor-like populations mimicking signatures of normal TDLUs. 
When exposed to conditions that mimic neoplastic progression, the organoids underwent cellular-
level phenotypic changes and organoid-level morphologic changes that could be quantified to 
stratify organoid responses. The one droplet – one organoid simplicity, the highly regular shape 
and size of the obtained organoids, and dramatic morphologic changes upon exposure to neoplastic 









3-5  Figures   
 
Figure 3-1. Organotypic expansion in MCF10A cells cultured in 3D hanging drop system. A) 
TOP PANEL: representative image of a normal terminal duct lobular unit (TDLU) in a human 
breast tissue sample (University of Michigan IRB HUM00050330) and inset showing an acinar 
structure comparing with organoid formation through 16 days, with expression of epithelial marker 
E-cadherin and hollow lumen formation. White arrows indicate 3D acinar structures within 
organoids. BOTTOM PANEL: 3D MCF10A organoid after 16 days by H&E showing a large 
hollow structure (scale bar = 200 μm), blue inset at 20X showing internal features (scale bar = 50 
μm), red inset at 60X magnification of a developing acinar structure (scale bar = 15 μm) (confocal 
images: CK5/6=green, CK18=red, nuclei=DAPI) and corresponding H&E image (scale bar = 15 
μm). B) diagram of conventional scaffold-based Matrigel culture or U-bottom spheroid formation 
compared with the hanging drop system. Legend shows characteristic sizes of acini, spheroid or 




Figure 3-2. Optimization of organoid formation technique in 384-well hanging drop (HD) 
system.  A) Representative brightfield images of 96-well ultra-low attachment (ULA) or 384-well 
HD 3D culture methods without FBS and with 10% FBS at days 1 and 8, and corresponding H&E 
sections at day 16. B) 0% and 2% Matrigel (v/v) at t=0, 12, and 72 hours (scalebar = 100 μm), and 
measurements of spheroid compaction efficiency rate at 0%, 1%, 1.5% and 2% Matrigel (v/v) at 
24, 48 and 72 hours (N=25 per subgroup). C) average diameter of benign, neoplastic, and cell mass 
organoid subgroups (MCF10A, MDA-MB-231, and 0% Matrigel (MG‒), respectively) and time-
course measurements at t=0 through day 16. Average diameter was measured by morphometric 
analyses in triplicate using N=10 organoids per subgroup, where best fit ellipsoids of round or 
irregular organoid morphologies were determined using Feret’s statistical diameter in ImageJ. 





Figure 3-3. Spheroid optimization assay at varying Matrigel concentrations (0%, 1%, 1.5% 
and 2% v/v) from time=0 to 72 hours (N=25 per subgroup). A) representative brightfield 
images, B) average spheroid diameter, C) percentage of droplets containing multi-spheres per 
droplet, called “loose cell aggregates”, and D) percentage of droplets that form one sphere per 













Figure 3-4. Comparison of stem cell vs differentiation marker expression for western blot 
analysis of MCF10A cells cultured in monolayer and 3D at days 4 and 8. “MG‒” identifies 
MCF10A spheroids seeded without Matrigel. MDA-MB-231 cells cultured in 2D were shown as 
a control. Antibodies used: E-cadherin, Vimentin, ALDH1, CD44, CD49f, EpCam, and β-actin. 











Figure 3-5. Organoid formation with normal MCF10A, MCF10A Matrigel-free (MG‒), and 
breast cancer MDA-MB-231 cells. Shown are representative images of the organoids at 8 days 
in 3D hanging drop with brightfield, H&E, and confocal images against Dapi, E-cadherin, CK5/6, 
and CK18. For comparison, images of a normal breast TDLU and an invasive ductal carcinoma 
from human tissues are shown with their characteristic morphology. Scalebar = 100 μm for 10A 
MG‒ and 200 μm for all others. Black or white arrows indicate 3D acinar structures within 
organoids. Distinct phenotypic features of normal or invasive TDLU (top panel, in vivo histologic 
images) share phenotypic similarities with in vitro organotypic structures in 3D hanging drop 
culture for benign (MCF10A), tumorigenic or neoplastic (MDA-MB-231), and non-tissue-like cell 
mass (10A MG‒) subgroups for the study of breast tumorigenesis and neoplastic progression. 
 








Figure 3-6. Summary of organoids developed in hanging drop. A) MCF10A vs MDA-MB-231 
organoids at days 4, 8, and 16 with a comparison of monolayer phase contrast images, H&E 
staining, and confocal imaging with Dapi, CK5/6, and CK18 status (expression results merged), 
B) comparison of H&E and collagen I staining from MCF10A, TGFβ1, CoCl2, and co-culture 






Figure 3-7. Organoids as models of neoplastic progression. Epithelial-to-mesenchymal (EMT) 
induction assays were developed for the study of neoplastic transformation in MCF10A organoids 
by TGFβ1 and CoCl2 treatment at Day 16, two well-studied agents known to induce EMT and 
neoplastic progression of MCF10A cells. Representative confocal images show altered expression 
of E-cadherin (red) and Vimentin (green) at 20X magnification, with enlarged inset at 60X 
showing regions of co-expression. Scale bar = 100 μm. Neoplastic progression has not been 
explored in free floatation, scaffold-free 3D culture and allows organoids to be readily quantified 




Figure 3-8. Organoids developed in hanging drop exhibit phenotypic changes when subjected 
to different conditions and co-culture with MSCs. Phenotypes in organoids developed in 
hanging drop with A) collagen I profiles for MCF10A, TGFβ1, CoCl2, co-culture, and MDA-MB-
231 at day 16 (N=5 per subgroup) compared with H&E and their associated fibrotic-like status via 
phenotypic quantitative analysis, B) H&E sections and confocal images at day 8 of normal 
MCF10A and co-culture organoids (MCF10A and MSCs seeded at a 1:1 ratio) showing spatial 
locations of MCF10A (blue) and MSC (red) cells within organoids, along with basal CK5/6 (green) 
status, and a schematic of typical morphology and phenotype based on epithelial/spindle-like 
features, or CK5/6 or Col1 expression, and C) CCN6 KO mouse mammary tumor-derived 
organoids with a live brightfield image at day 20, H&E and IHC sections for Ki67, and Cleaved 







Figure 3-9. Evaluation of organoid morphologic and phenotypic parameters. A) Morphology 
parameters: average organoid diameter, sphericity, and hollowness, and phenotype parameters: 
epithelial/cell-cell contact (E-cadherin+), mesenchymal-like (spindle-like+), basal/progenitor 
(CK5/6+), and fibrotic-like (Collagen I+). Phenotypic parameters were based on the percentage of 
positive stained cells per organoid (N=5 organoids per subgroup, triplicated, 75-150 cells analyzed 
per section). Organoids were categorized as non-tumorigenic (MCF10A), tumorigenic (MDA-
MB-231) and neoplastic (co-culture, TGFβ1 and CoCl2 treated). B) table of the combined 
morphologies and phenotypes represented in a table showing results of quantitative measurements 
of all organoid subgroups at day 16. For morphologic parameters (N=10 per group): * = Sphericity 
> 0.75 on scale of [0 ‒ 1] is “spherical,” < 0.5 is “irregular,” and ~ 0.5-0.75 is “semi-spherical”. † 
= % Hollowness > 0.75 is “hollow,” 0.5-0.75 is “partial filled,” and < 0.5 is “filled,” where “‒” 
indicates no observed expression, “++” indicates a percentage of positive cells per organoid > 



















Chapter 4 ‒ Conclusion 
 
4-1  Discussion and Future Directions 
High-throughput translational studies are paving the way for a new era of improved clinical 
diagnosis and treatment options by combining patient data with available in vitro and in vivo 
models. Understanding the key signaling drivers of neoplastic transformation will enable a diverse 
range of integrative approaches that combine information on manifold scales and platforms, 
including human patient tumors and animal model data, 3D organoid screening and biobanking, 
and multi-omics technologies to analyze these on multiple molecular levels. Aggressive breast 
cancers such as triple-negative and metaplastic carcinomas are highly complex and heterogeneous 
tumors, but there is currently a drastic lack of knowledge on their underlying pathogenesis. This 
has resulted in a severe deficiency of models of oncogenic progression and thus, a lack of available 
therapies, especially in the case of metaplastic breast carcinoma, which is more aggressive and 
rare compared to TNBC due to the presence of heterologous non-glandular components displaying 
uncommon patterns of differentiation that are very abnormal to reside in the breast (spindle, 
squamous and sarcomatoid). Here we have introduced evidence that both human and mouse 
models, together with 3D organoid and multi-omics data are capable of recapitulating key 
molecular drivers of known histological features, and that it is possible to correlate phenotypic 
information about subtype-specific histologies on multiple molecular levels, such as comparing 
genomic and proteomic levels to tissue presentation via imaging data (histologic and 
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morphologic). This enables investigators to understand the pathogenesis of this complex disease, 
how these differentiation patterns arise, and what set of markers can be tested as novel therapies. 
In the future, studies will need to undertake the difficult task of seamlessly integrating the 
information generated from these multi-modalities directly with omics technologies, which are 
critical for elucidating multi-level information (e.g. thousands of data points on the expression of 
genomic variants, proteins, etc). Pathogenesis occurs as a complex orchestration among all these 
molecular and cellular levels, resulting in the range of heterogeneity we see within these tumors at 
the tissue level, and therefore it is of critical importance to assemble these data from large-scale 
and small-scale cohorts and create well-annotated databases in a patient stratified format to easily 
allow identification of novel biomarkers in the selection of therapeutically operable targets. 
Here we presented a quantitative proteomic landscape of human MBC, a subtype of TNBC 
with a defining histology, frequent therapy resistance, and distant metastases [120]. Using tissue 
resources from patients and from an MBC spindle mouse model, robust proteomics and novel 
bioinformatics tools we demonstrated shared and subtype-specific altered proteomes present in 
spindle, squamous and sarcomatoid MBC, providing insights into the biology of this aggressive 
form of breast cancer and offering unique opportunities for precision medicine.  
Despite the impact of protein expression on tumor phenotypes and clinical behavior, our 
knowledge on the protein landscapes of human breast cancer, and how differential profiles 
contribute to breast cancer phenotypes is very limited. Advances in proteomic methodology and 
bioinformatics technologies have enabled detailed characterization of breast cancer [19], [95]. 
However, studies to date have focused on frequent subtypes of breast cancer, with few to no MBC 
cases and normal breast tissues.   
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Upon comprehensive analyses we revealed common and subtype-specific differences 
among MBCs and their relationship with TNBC. Relative to TNBC, the proteome of MBC is 
enriched in EMT, and has a highly activated ECM, and reduced oxidative phosphorylation. These 
data are consistent with our previous studies showing that MBC express proteins involved in EMT, 
which might contribute to a more stem-like and aggressive phenotype compared to TNBC. Also, 
transcriptome studies have shown that MBCs cluster as basal-like and claudin-low [57], [121] and 
subtype-specific proteins and pathways emerged when we compared proteomic profiles of spindle, 
squamous and sarcomatoid tumors. A distinct feature of spindle MBCs was upregulated E2F and 
MYC signaling, ribosomal proteins, nuclear processing, and translational events. These are 
intriguing findings since recent reports have shown a possible synergy exists at the E2F/MYC axis, 
which is known to be involved in the cell cycle, chromatin remodeling and EMT, where ribosome 
biogenesis and increased translation play an essential role [122], [123]. These findings also suggest 
that spindle MBC has a deregulated balance between translation and metabolic pathways.  
Squamous MBC on the other hand, was found to have predominantly upregulated inflammatory 
responses (e.g. IFN-γ, TNFα, PI3K/MTOR), keratinization, and widespread cell adhesion marker 
expression and decreased oxidative phosphorylation, E2F/MYC signaling, and sarcomatoid MBC 
exhibited prominent profiles in extracellular matrix signaling and increased EMT program 
compared to other MBCs, possibly owing to it being analogous to a differentiation pattern along 
mesenchymal lineages [124]. Also, we observed that in general, there is no significant difference 
in P53 and PI3K pathway between MBCs and TNBC, and that while our proteomic analysis 
suggests that spindle, squamous and sarcomatoid MBCs and TNBC may share initial neoplastic 
events, each MBC subtype appears to have unique and active differentiation programs. 
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MBC are chemoresistant and metastatic, but the underlying molecular events and driver 
pathways are unclear and there are no effective treatments currently available [48], [52]. The 
heterogeneity of MBC has been investigated at the genetic level [58], [60], [125], however the 
relationship between genomic and proteomic alterations is unknown. Recent reports at the genetic 
level show that MBC harbor somatic mutations in TP53, PI3K/MTOR and Wnt signaling pathway 
genes [60], but no underlying subtype-specific mutational profiles in MBCs have been uncovered. 
Our whole exome sequencing analyses of 10 paired tissue samples of MBC and normal breast 
tissue from the same patient cohort identified somatic mutations common to all MBCs in TP53, 
MUC17, CRYBG2, PLEC, and ZNF681, where only TP53 has been previously reported in MBC. 
While spindle and squamous MBC exhibit overlapping mutational profiles of genes involved in 
RNA metabolic processes and actin filament binding, sarcomatoid tumors harbor distinct 
mutations in MAPK, WNT, protocadherin cluster genes, calcium binding and ECM organization. 
Together, these findings demonstrate novel somatic mutations in MBC tumors, distinct mutational 
profiles of sarcomatoid MBC compared to the overlapping landscape of spindle and squamous 
MBCs, which underscore the importance of elucidating the proteomic landscape to nominate 
subtype-specific proteins and pathways, especially between tumors with spindle and squamous 
differentiation, that may lead to novel treatment targets. 
Quantitative proteomics results from our mouse model of spindle MBC using MMTV-
Cre;Ccn6fl/fl mice demonstrated a significant overlap with human spindle MBCs, with shared 
enrichment in E2F, MYC, EMT, and ribosomal proteins. Our analyses further pinpoint a set of 17 
upregulated and 19 downregulated proteins commonly deregulated in mouse and human spindle 
MBCs which have not been previously considered in these tumors. The 19 downregulated proteins 
have functions in metabolic processes, while of the 17 upregulated proteins, the majority are 
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ribosomal proteins. These data validate the MMTV-Cre;Ccn6fl/fl mouse model as a relevant tool to 
investigate and test new targets for spindle MBC, and we suggest this overlapping set of proteins 
between mouse and human MBCs represents a set of therapeutically operable targets. Our studies 
could pave the way towards mechanistic and functional investigations of these proteins in 
elucidating the underlying biology and pathogenesis of spindle MBC.  
In addition to subtype specific tumor signatures, our study uncovered a stromal cell 
expression pattern in MBCs in the form of a significant number of mesenchymal and stromal 
proteins being downregulated (e.g. CD34, CD36, CD59, CD209 CD248). The stromal profile is 
intriguing and has not been previously considered in relation to metaplastic breast carcinoma, and 
hints the interplay of cellular transitions are critical to either stemness, invasion, or both, and that 
processes like EMT, angiogenesis and other unexplored events like EndMT (endothelial-
mesenchymal transition) might also be simultaneously involved in oncogenic transformation 
[127]. 
In summary, we presented a patient cohort that describes a common proteomic landscape 
of MBC relative to TNBC, and highlights the existence of specific protein signature that underly 
the different histopathological subtypes of human MBC. We also show that quantitative 
proteomics assisted in refining the somatic mutational landscape of MBCs and allowed for the 
distinction of the MBC tumor subtypes. We provide evidence for a significant overlap between 
MMTV-Cre;Ccn6fl/fl spindle MBC mouse model and human disease, which consist of a common 
histopathology on the protein level, and validate that this mouse model can be utilized for testing 
new treatments and mechanistic investigations on the development of spindle MBC. The subtype-
specific proteomes of MBC tumors highlight an ability to impact precision therapies to improve 
the survival of women with this aggressive form of breast cancer.  
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4-2  Translational applications with 3D modeling 
Modeling neoplastic progression in mammary organoids with multiple phenotypes and  
mixed cell populations remains a challenge [134]. Here, we have developed a 3D mammary gland-
like structure that resembles morphological and phenotypic aspects of the normal breast and allows 
highly reproducible quantification in vitro.  
Early work in the field discovered that human breast cancers originate from cells within 
the terminal duct lobular unit (TDLU), a composite of a duct and several lobules. Here, we selected 
MCF10A to model normal breast cell function. Although MCF10A has been previously 
established in 2D and scaffold-based 3D cultures using Matrigel [10], [13], [71]), they typically 
are limited in tissue-specific marker expression, physiologic sizes (50-200 μm), and are known to 
dramatically influence stem cell populations. Our MCF10A organoids in the hanging drop system 
potentially mitigate these issues, and offer increased flexibility in modeling neoplastic progression 
while keeping certain populations intact, such as progenitors. We developed MCF10A organoids 
that were strikingly larger compared to other 3D models of MCF10A, and they ranged from 900-
1200 μm with an average diameter of 1070 ± 105 μm after 2 weeks in culture. They also exhibited 
multi-acinar structures resembling aspects of normal breast TDLU. Recently, Qu and others [75] 
have investigated the use of MCF10A as an accurate model of normal breast, and found mixed 
luminal and basal expression of MCF10A acini. Our findings also confirmed a mixed luminal and 
basal expression of MCF10A organoids. Cytokeratin status has been intensely studied in clinical 
pathology on breast lesions and benign tissue, with distinct phenotypes described as 
stem/progenitor (CK 5/6+), glandular progenitor (CK 5/6+ and CK 18+), and committed glandular 
(CK 18+) [9],[138]. Interestingly, a population of CK 5/6+ cells on the basolateral side of 
MCF10A organoids appeared to co-express CK 18, suggesting glandular progenitor status.  These 
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findings seem to suggest that the MCF10A model, when grown into 3D organoids, recapitulates 
some of the cellular heterogeneity present in normal breast TDLU. The size of the organoids may 
reflect not only the tightness of cellular interactions within the organoid but may also be a crucial 
determinant of cell biology [136]. As seen in recent organotypic culture studies, larger sphere sizes 
may correlate with the ability of organoids to generate and display multiple phenotypes in 3D, 
seen in other cell types such as the development of multilayered optic cup structures with hESCs 
growing to ~550 μm diameters [130], and human brain organoids of ~2 mm diameters that 
produced regions of multiple cell types [137]. Overall, this ability to form physiologic acinar 
structures in 3D is generally thought to require a scaffold setting because the support matrix 
provides the necessary pseudo-basement membrane. However, based on our studies, we postulate 
that the scaffold material itself might limit organoid expansion, by mechanical constraints and/or 
limiting the supply of critical nutrients [139], and that the actual concentration of Matrigel or other 
scaffold substrates used in 3D culture models should be lowered dramatically, and only used upon 
cell seeding to enable differentiation and self-organization activities.  
Available data suggest that hanging drop culture might provide advantages over other 3D 
spheroid assays for achieving organoid expansion, such as conventional 3D gel embedded or on-
top Matrigel culture, or microfluidic systems for cancer progression modeling [141],[78] which 
show significant restriction in size (<300 μm diameter) and proliferation potential, possibly due to 
mechanical confinement. Also, when using microsensors, the oxygen levels of multi-spheroids 
grown in conventional U-bottom 96 well plates is greatly reduced after 18 hours, while hanging 
droplets with only one spheroid had stabilized oxygen values [139]. Our observation of irregular 
morphologies, lumen filling, and no acinar formation in 96 well U-bottom plates, suggests that 
hanging droplets are organoid-supportive by providing more oxygen, enhancing autocrine effects 
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considering the use of small media volumes. In addition, MCF10A cells were not able to aggregate 
into tight single structures without FBS at seeding, consistent with literature, in which FBS was 
shown to augment cellular differentiation [130]. 
When looking more closely at the enhanced differentiation pattern of MCF10A organoids, 
we demonstrated the presence of a stem cell population where previous studies of MCF10A cells 
in 3D Matrigel systems were not able to observe stem cell populations and actually reported a loss 
of stem/progenitor markers when moving from 2D to 3D systems [75]. This suggests the MCF10A 
cell line, when using drastically lower concentrations of Matrigel in 3D hanging drop, could 
maintain a self-renewing progenitor population. This is a potential advantage of growing cells in 
a free-floatation context, whereby the investigation of stem cell populations in real-time can be 
readily monitored despite having less physiologically relevant ECM mimicry compared to 
conventional 3D scaffold-based platforms.  
Overall, the two major substrata used in 3D breast models, collagen I gels and Matrigel, 
are essential for providing the biophysical context  and cues for mimicking the microenvironment, 
although it remains challenging for 3D systems to mimic specific features of the in vivo case [136]. 
Organoids grown under free suspension may experience less pressure cues than scaffold-
embedded culturing, which might be a potential drawback. The lack of ECM biophysical forces 
could explain why MCF10A organoids undergo substantial expansion to approximately twenty-
five times the size of normal breast acini, but this ability to expand highlights a tight cellular 
commitment to the normal morphogenetic program. Moreover, a major disadvantage of gel 
systems is their restricted ability to express tissue-specific markers [154]. Our data support the 
idea that a 3D free-floatation context might provide a more permissive environment for 
differentiation.  
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We also showed that MCF10A could undergo malignant neoplastic progression by 
exogenous treatments rapidly, within days of treatment, and that it is relatively easy to quantify 
both morphology and phenotypic properties of such organoid states. We selected treatment with 
TGFβ and the hypoxia-mimetic agent, CoCl2, given their reported effect in induction of EMT and 
malignant transformation in breast cancer, and demonstrated that the hanging drop organoid 
system allows expansion of cell populations with normal and neoplastic phenotypes, which can be 
applied to the study of breast tumorigenesis. Unexpectedly, our results revealed the previously 
unknown ability of MCF10A cells to undergo de novo synthesis and deposition of collagen I upon 
EMT induction. Since conventional 3D gels often make use of collagen-containing matrices, the 
production of collagen from transformed normal epithelial cells would be an indiscernible or 
challenging feature to both measure and capture.  
Due to growing interest in patient tumor derived organoids for purposes of biobanking 
[152] and single cell sequencing [153], which have focused on the primary epithelial cell 
compartment, there is a great need to unravel patient tumor heterogeneity with high-throughput 
quantitative approaches. Here, we have provided a proof-of-concept that our 3D organoid platform 
is useful to study the microenvironment, particularly epithelial-stromal cross-talk during 
neoplastic initiation and progression. This might offer an ideal system to test new therapies to 
block stromal pro-tumorigenic influences on epithelial cells. In summary, our results indicate that 
benign breast cells such as MCF10A may have an intrinsic plasticity that is revealed by using a 
gel-free culture platform. We also show that the de novo remodeling processes can easily be 
detectable by histological methods. From a clinical perspective, the 3D organoid system can be 
applied to study rare and aggressive carcinomas such as TNBC and MBC, using patient primary 
tissues and performing a panel of treatments. 
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Despite an increase in studies using 3D tumor models in recent years, there remains a lack 
of standardization in spheroid and organoid analyses. Although parameters such as volume, 
sphericity, and area are very useful, they can be quite variable in the literature, stemming from 
inconsistencies in reproducibility and uniformity. Others have also noted overall shape is a highly 
variable parameter yet is an important indicator of tumorigenicity, so finding a quantifiable metric 
that correlates well with biological relevance will be a critical step going forward. Thus, as our 3D 
platform is a highly-reproducible method, future investigations involving patient-derived 
organoids which facilitate the study of large-scale drug screening and patient organoid biobanking 
([158]) will become necessary in order to guide precision therapies.  
4-3 Future Directions 
In chapter 2, we identified specific pathways and drivers unique to each MBC, and in 
chapter 3 we optimized a 3D model capable of testing these therapeutically operable candidates 
using patient tissues. Future investigations are necessary to validate the set of genes/proteins we 
identified for each MBC subtype building upon our proteomics and WES analysis. A general 
workflow for such future work could be to validate these results by a combination of IHC, 
integrative multi-level omics profiling, functional assays, and 3D patient-derived organoid 
treatments.  However, it is important to note that each MBC should be analyzed as a separate 
disease and experiments should be tailored to their major phenotypes. Below, we outline a brief 
translational vignette going forward for the analysis of MBC tumors:  
Spindle MBC: These tumors tend towards an undifferentiated, EMT-like mesenchymal phenotype. 
Studies can perform IHC on E2F, MYC, and ribosomal proteins, “RP” (e.g. RPS17, RPL28, RPL6, 
RPL15), followed by an integrative analysis of proteome and phosphoproteome to interrogate the 
E2F/MYC/RP axis to reveal the connectivity of key transcription factors (“TFs”) and kinases that 
 113 
control the protein translation machinery. This will provide a proof-of-principle experiment for the 
reconstruction of the connectivity between TFs and kinases using proteomic and 
phosphoproteomic data along this signaling cascade and reveal candidate TFs (e.g. protein 
abundance vs phosphorylation levels) and screen each TF by functional phosphosites using a 
known kinase-substrate database. Also, since we found mutations in AHNAK and PI3K/MTOR 
genes, these experiments could reveal links to these key pathways and ribosome biogenesis and 
provide functional responses of oxidative phosphorylation. In addition, the MMTVcre;Ccn6fl/fl KO 
mice can be further investigated to identify actionable targets of CCN6 treated mice compared to 
BSA controls and normal mammary mouse tissues with a follow-up proteomics analysis. 
Organoids will also be developed using human and mouse primary tissues and subjected to CCN6 
treatment. 
Squamous MBC: Tumors present with epithelioid status and are more similar to a squamous cell 
carcinoma phenotype, have a prominent immune profile, and a hypothesis is that these tumors 
could be potentially responsive to immunotherapies. Genomically, these tumors were observed 
with mutations in PI3K/MTOR and MUC17, and were upregulated at the protein level in several 
inflammation-associated pathways (IFNγ, TNFα, NFκB). We also suggest an integrative analysis 
using IHC of these immune-related markers, and proteomics and phosphoproteomics profiling 
analysis. However, for these tumors, one could instead interrogate T cell activation and 
interconnected functional modules of TF-kinase signaling and TF-TF interactions to identify 
important immune regulators. Single-cell sequencing can then be used to cluster immune cells 
from tumor cells and provide insight into tumor infiltrating T cell phenotypes. A database of 3D 
patient-derived organoids can be established using a biobanking method of patient tumors and a 
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screening of these organoids using panel of available immunotherapies (e.g. PD-L1 inhibitor, 
durvalumab). 
Sarcomatoid MBC: This metaplastic component tends toward a more differentiated, EMT-like 
mesenchymal phenotype, and was the only MBC subtype to present a similar genomic and 
proteomic profile with molecular and protein alterations in extracellular matrix receptor, cadherin, 
and calcium ion signaling. For example, IHC analysis could specifically focus on a panel of 
protocadherin cluster, which had a novel mutational profile in these tumors. A proteomics and 
phosphoproteomics analysis could potentially resolve the cadherin interactome and identify cell-
cell adhesion activity, and demonstrate which kinases are involved in regulating cadherin activity 
comparing sarcoma tumor samples as controls. We could also examine cadherin signaling by 
cadherin-dependent adhesion functional assays, for example by fluorescently labeled cadherin 
fusion proteins (Ca+2 dependent adhesion) and Ca+2 binding properties (e.g. immunoblotting on 
the levels of N-cad or VE-Cad vs. interactions with β-catenin). In addition, single-cell analysis 
using sarcomatoid vs. sarcoma samples can cluster mesenchymal cell phenotypes to elucidate 
whether sarcomatoid MBC tends more toward the molecular properties of epithelial or 
mesenchymal tumors. If the latter, a hypothesis is that sarcomatoid tumors should be treated like 
other sarcomas, and 3D patient-derived organoids might involve treatments using a combination 
of doxorubicin and ifosfamide. 
Due to the rarity of the disease limited access to available patient tumor samples, a typical 
study might utilize a small patient cohort. A future strategy for rare tumor analysis is to build a 
growing database of metaplastic carcinoma samples that can assemble multi-level omics datasets 
(from both primary tissues and patient-derived organoids) to better consolidate information in a 
patient-stratified format.  
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4-4 Final Thoughts  
Our proteomic and genomic data sets suggest that a clear snapshot of the microenvironment 
brings a molecular context to processes like EMT and metabolism, which could point to which 
features of cellular plasticity such as CSC phenotypes that might be dominant or enriched within 
a particular MBC subtype in seeking novel candidate therapies. In addition, the data indicates that 
there may be certain subtype-specific differences in MBC that may allude to the presence of 
metastable E/M states along an epithelial (E) to mesenchymal (M) spectrum [28]. EMT was the 
top activated process compared to other TNBCs on the protein level, and this feature is also the 
most widely reported by histological evidence. Within MBC subtypes, it might suggest that 
squamous tends toward a basal or epithelioid phenotype that is apparently driven by inflammation, 
whereas spindle tends toward a mesenchymal status but is more poorly differentiated and consists 
of a seemingly “primitive” ECM relative to sarcomatoid. Among the MBCs, sarcomatoid 
presented both histologically and proteomically with higher mesenchymal status (e.g. higher EMT 
and ECM signaling) than spindle and squamous forms, possibly indicating a more extensive and/or 
well-differentiated ECM. Thus, our results broaden the notion of the conventional EMT enriched 
feature in MBCs suggesting that each MBC might reside in much different stages of EMT/MET, 
and general stemness states that influence their invasiveness. We also showed a proteomic link to 
genomic features of MBCs, which could prompt future pathognomonic studies that explore how 
each MBC subtype are tightly regulated, and how their complex epithelial‒mesenchymal 
“metastable” phenotypes might contribute to increased aggressiveness and poor survival 
outcomes. In addition, the knowledge of proteomic and genomic alterations in MBC could be 
further tested using our 3D neoplastic breast organoid platform that produces highly uniform, 
reproducible 3D structures that are easy to standardize against a variety of parameters. MCF10A 
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organoids contained cells of multiple phenotypic lineages, including those along the epithelial and 
mesenchymal spectrum, and those that include progenitor-like populations. Our 3D organoid 
platform also revealed the ability to quantify and define cellular-level phenotypic changes and 
organoid-level morphologic changes that could be stratified at the patient level if primary tissues 
were used in this system. The one droplet – one organoid simplicity and rapid treatment assay 
strategy opens the door for standardization in a high-throughput testing.  
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Appendix 1 ‒ MMTVcre;Ccn6fl/fl metaplastic carcinomas express IGF2BP2, HMGA2 and 
EMT markers and are recapitulated in mouse derived organoids 
 
The following are work performed by the Kleer lab, in which I was a co-author and 
contributed to development of mouse-derived organoids from primary tissues, sectioning, 
histology and immunohistochemistry. In this study by McMullen, E. R. et al. CCN6 regulates 
IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast. Breast Cancer Res. 
Treat. 172, 577–586 (2018), our lab generated a novel MMTVcre;Ccn6fl/fl knockout mouse using 
the Cre-lox system to specifically study the effect of Ccn6 deletion in the mammary epithelium. 
Using this model, we discovered that Ccn6 is important for normal mammary gland development 
and tumorigenesis. MMTVcre;Ccn6fl/fl mice mammary glands had fewer terminal buds, 
decreased breast complexity, and displayed ductal hypoplasia when compared to wild-type mice. 
MMTVcre;Ccn6fl/fl mice developed mammary tumors morphologically and transcriptionally 
similar to high-grade spindle and squamous human metaplastic carcinomas.  
IGF2BP2 (insulin-like growth factor 2 mRNA binding protein 2/IMP2) is an oncofetal 
protein important for embryonic development and downregulated in normal adult tissues, which 
functions by binding and stabilizing mRNAs to extend their half-life. In breast cancer, IGF2BP2 
overexpression is associated with decreased cell adhesion and migration. HMGA2 (high mobility 
group AT-Hook 2), another oncofetal protein, functions as an architectural transcription factor. 
Similar to IGF2BP2, HMGA2 contributes to embryonic development and tumorigenesis. 
HMGA2 levels are associated with migration, EMT, and worse outcome in breast cancer. 
IGF2BP2 and HMGA2 have a reciprocal relationship as IGF2BP2 prevents Let7-mediated 
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HMGA2 inhibition and IGF2BP2 gene transcription and protein expression are highly dependent 
on HMGA2. MMTVcre;Ccn6fl/fl mice tumors recapitulate human high-grade triple-negative 
spindle/squamous metaplastic carcinomas. However, whether they express IGF2BP2 and 
HMGA2 proteins is unknown. Here, we found that all MMTVcre;Ccn6fl/fl tumors showed 
increased expression of IGF2BP2 and HMGA2 by immunohistochemistry. IGF2BP2 protein was 
expressed in the cytoplasm of cancer cells, while HMGA2 was exclusively nuclear (Fig. A-1). 
IGF2BP2 and HMGA2 expression were low in adjacent normal mammary epithelium of 
MMTVcre;Ccn6fl/fl metaplastic carcinomas (Fig. A-1). Our laboratory has previously reported 
that CCN6 knockdown in non-tumorigenic breast cells induces a spindle and invasive phenotype 
with up-regulation of the EMT transcription factors SNAI1 and ZEB1. Consistent with their 
spindle morphology, MMTVcre;Ccn6fl/fl tumors also had upregulated expression ZEB1 and 
SNAI2 (Fig. A-1). Immunostaining of organoids derived from MMTVcre;Ccn6fl/fl tumors 
demonstrated high expression of IGF2BP2 and HMGA2 proteins in the spindle cancer cells, 




Figure A-1: MMTV-cre;Ccn6fl/fl metaplastic carcinomas express IGF2BP2, HMGA2, and 
EMT markers. A) Histological sections of MMTVcre;Ccn6fl/fl tumors showing low CCN6, high 
IGF2BP2 and HMGA2 proteins and upregulated expression of EMT transcription factors ZEB1 
and SNAI2. Arrows indicate normal glandular structures in the murine mammary gland. B) 
Organoids developed from MMTVcre;Ccn6fl/fl tumors demonstrating a spindle morphology and 






Appendix 2 - Recombinant human CCN6 protein reduces IGF2BP2 an HMGA2 expression 
and regulates metaplastic tumor growth in vivo 
 
The Kleer lab reported that recombinant human CCN6 protein regulates IGF2BP2 and HMGA2 
expression, and is sufficient to reduce growth of MMTV‑cre;Ccn6fl/fl metaplastic 
carcinomas in vivo [108]. As CCN6 is a secreted protein, we used recombinant human 
CCN6 (rhCCN6) to elucidate its role on IGF2BP2 and HMGA2 regulation. We employed MDA-
MB-231 and −468 cells, which are TNBC cells with a spindle morphology and gene expression 
profiles of mesenchymal-like and basal type-A breast carcinomas, respectively. Addition of 
rhCCN6 was sufficient to reduce IGF2BP2 and HMGA2 protein levels in both breast cancer cell 
lines (Figure A-2). Furthermore, ectopic overexpression of CCN6 in MDA-MB-231 cells 
reduced ZEB1 and SNAI2 protein levels compared to controls. The effect of rhCCN6 was 
investigated in vivo, using orthotopic syngeneic model by transplanting MMTVcre;Ccn6fl/fl 
tumors into the mammary fat pads of mice with the same genetic background (FVB). Mice were 
treated with rhCCN6 (1 ng/g, i.v., twice a week, initiated 2 weeks after transplantation) or BSA 
in the same regimen. rhCCN6 significantly reduced tumor growth, induced a morphological 
change from spindled towards epithelial, and reduced the expression of IGF2BP2 and HMGA2, 
compared to BSA treatment (Figure A-2). These findings demonstrated that CCN6 regulates 
IGF2BP2 and HMGA2 signaling in spindle carcinoma cells and that rhCCN6 is sufficient to 
reduce tumor growth in vivo. 
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Figure A-2: Human recombinant CCN6 protein reduces expression of IGF2BP2 and 
HMGA2 and regulates metaplastic tumor growth in vivo. A) MDA-MB-231 and −468 breast 
cancer cells with spindle morphology were treated with rhCCN6 or BSA. B) MMTVcre;Ccn6fl/fl 
tumors were implanted in the mammary fat pads of 8–10 weeks old female MMTVcre;Ccn6fl/fl 
mice to avoid the possible contribution of microenvironment-derived CCN6 on tumor growth. 
Mice were treated with rhCCN6 (1 ng/g) or BSA (1 ng/g) i.v. twice a week starting 2 weeks after 
tumor implantation. Shown are histological sections of the tumors after 3 weeks of treatment. 
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